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Chitosan oligosaccharide (CSO) derivatives were successfully 
synthesized and used for the development of self-assembled nanoparticles for 
targeted delivery of doxorubicin (DOX) as a model of anticancer drug. The 
novel amphiphilic polymer, arachidyl chistosan oligosaccharide (CSOAA), 
was firstly synthesized in this study. In addition, CSOAA was further 
developed by grafting polyethylene glycol (PEG) (CSOAA-PEG) and 
diethylenetriaminepentaacetic dianhydride (DTPA)-Gadolinium (III) 
(CSOAA-DTPA-Gd) on the CSOAA backbone for a prolonged drug 
circulation time in blood stream and improving intensity of contrast agent for 
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magnetic resonance imaging (MRI) of neoplastic lesions, respectively.  The 
CSOAA formed self-assembled nanoparticles with nano-sized less than 200 
nm in diameter, narrow particle size distribution, and low critical aggregation 
concentration (CAC) that could imply to stability of the nanoparticles.  DOX-
loaded CSOAA nanoparticles exhibited sustained drug released profile and 
improved drug releasing in acidic condition. In vitro cellular uptake of DOX 
in FaDu cells of the NPs-treated group were higher than free DOX group.  In 
vivo antitumor efficacy of DOX-loaded CSOAA NPs was also verified in 
FaDu tumor xenografted mouse model. In the CSOAA-DTPA-Gd studies, the 
amount of Cy5.5-labled nanoprobes taken-up by FaDu and Hep-2 cells, as 
observed by confocal laser scanning microscopy (CLSM), increasing 
according to incubation time (up to 12 h). A phantom study of CSOAA-
DTPA-Gd nanoprobes showed a T1-positive contrast-enchancing effect, 
compared to that of the commercial formulation (Gd-DTPA; Magnevist®). In 
the CSOAA-PEG studies, the stability of nanoparticles were investigated that 
the mean diameter both of CSOAA and CSOAA-PEG nanoparticles remain 
in DDW over 72 h, but the mean diameter of CSOAA-PEG nanoparticles 
remained relatively constant in serum over 72 h, compared with CSOAA 
nanoparticles (changed of 20.92% and 223.16%, respectively). The uptake of 
DOX in the nanoparticles by K562 human leukemia cells was higher than 
DOX solution. From the pharmacokinetic studies in rats, in vivo clearance 
rate of DOX in the CSOAA-PEG nanoparticles group was slower than other 
groups (CSOAA nanoparticles and DOX solution groups), subsequently 
extending the circulation period. All of the results suggested that the 
synthesized CSO derivatives could be used for preparation in self-assembeld 
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nanoparticles as an effective candidate for targeted anticancer drug delivery 
and neoplastic diagnosis system. They could be applied for the other 
anticancer drugs to improve the specificity uptake of drugs at tumor site, 
thereny optimizing pharmacokinetics, antitumor efficacy, and side effect. 
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PART I. Chitosan oligosaccharide–arachidic acid-






Polymeric nanoparticles have been widely investigated as drug carriers for anti-
cancer agents (Cho et al., 2011; Choi et al., 2012; Kaida et al., 2010; Kolishetti et al., 
2010; Yoon et al., 2012). Self-assembly based on amphiphilic polymer has been 
widely investigated because it has many interesting properties. Amphiphilic 
polymers can form stable nanoparticles composed of a hydrophobic core and a 
hydrophilic shell in an aqueous environment. Poorly water-soluble drugs can be 
encapsulated in the internal hydrophobic cavity, which can improve their solubility 
and bioavailability (Alibadi et al., 2005; Kwon, 2003; Li and Tan, 2008). The nano-
size and hydrophilic shell of these self-assembled nanoparticles can impede 
elimination by the reticuloendothelial system (RES) and have an enhanced 
permeability and retention (EPR) effect as a passive targeting strategy, leading to 
effective accumulation of drugs at the tumor region (Maeda et al., 2000).  
Doxorubicin (DOX) is an anthracycline antibiotic that is commonly used in the 
treatment of various types of cancer, such as hematological malignancies, breast 
carcinomas, ovarian carcinomas, bronchogenic carcinomas, and soft-tissue sarcomas. 
DOX has also exhibited therapeutic effects for head and neck cancer (Airoldi et al., 
2008), which includes several types of tumor localized in the oral cavity, nose, throat, 
sinuses, and salivary glands (Cho et al., 2012a). The response rate for anti-cancer 
therapeutics is known to be relatively low in head and neck cancer, with a survival 
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benefit of about 10 weeks for patients with recurrent/metastatic disease (Reuter et 
al., 2007). Although DOX shows high potential anti-cancer efficacy, its clinical 
application is limited because of its severe side effects, especially cardiotoxicity and 
myelosuppression (Kratz et al., 2007; Wildiers et al., 2008). Therefore, it is thought 
that tumor-targeting strategy can minimize these side effects (Cho et al., 2012b). 
Chitosan (CS) is a linear cationic polysaccharide composed of randomly 
distributed β-(1-4)–linked D-glucosamine and N-acetyl–D-glucosamine units, 
produced by the deacetylation of chitin. CS has been regarded as an attractive 
material for the development of drug delivery systems due to its biocompatibility, 
biodegradability, and low toxicity (Kumar et al., 2004; Muzzarelli and Muzzarelli, 
2005). Moreover, CS has free primary amino groups, allowing for further chemical 
modification. However, the major drawback of CS is its poor solubility at 
physiological pH. Recently, many researchers have investigated chitosan 
oligosaccharide (CSO), a low-molecular-weight CS, because it can be soluble in 
water and several organic solvents under physiologically relevant conditions (Vishu 
Kumar et al., 2004). CSO has been modified with hydrophobic residues, such as 
alkyl groups, cholesterol, tocopherol, and deoxycholic acid (Chae et al., 2005). These 
hydrophobically modified CSOs can form self-assembled nanoparticles, which can 
be used as carriers for tumor-targeted drug and gene delivery. 
In this study, arachidic acid (AA), as a fatty acid, was conjugated to a CSO 
backbone to make an amphiphilic CSO derivative. DOX was loaded into the self-
assembled nanoparticles based on chitosan oligosaccharide–arachidic acid 
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(CSOAA). The physiochemical properties of DOX-loaded CSOAA-based 
nanoparticles, such as particle size, zeta potential and morphology, and in vitro drug 
release behavior were investigated. In vitro cytotoxicity and cellular uptake 
efficiency were evaluated in head and neck cancer cells, and in vivo anti-tumor 
efficacy were also assessed in the head and neck cancer xenografted mouse model. 
 




 Chitosan oligosaccharide (CSO; average molecular weight = 5 kDa, degree of 
deacetylation > 90%) was purchased from Kitto Life Co., Ltd. (Seoul,Korea). 
Arachidic acid (AA), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), 
N-hydroxysuccinimide (NHS), and deuterium oxide were purchased from Sigma-
Aldrich Co. (St. Louis, MO, USA). Dimethylsulfoxide-d6 (DMSO-d6) was purchased 
from Cambridge Isotope Laboratories Inc. (Andover, MA, USA). Doxorubicin 
hydrochloride (DOX HCl) was obtained from Boryung Pharmaceutical Co. (Seoul, 
Korea). Minimum essential medium (MEM), penicillin, streptomycin, and fetal 
bovine serum (FBS) were obtained from Gibco Life Technologies, Inc. (Grand 




2.2. Synthesis and characterization of CSOAA 
 
Amphiphilic CSOAA was synthesized from CSO and AA. Briefly, CSO (0.2 
mmol) and AA (0.6 mmol) were dissolved separately in 20 ml DMSO each at 50°C 
for 15 min and cooled down at room temperature. Carboxyl groups of AA were 
activated by adding EDC and NHS (1.5 mol/mol AA) and it was stirred at room 
temperature for 30 min. Then, activated AA solution was dripped into the CSO 
solution for 5 min. The coupling reaction was conducted for a further 12 h, and then 
4 ml of deionized distilled water (DDW) was added. The pH of the mixture was 
adjusted to 3.5 with 1 N HCl and stirred for 30 min. The mixture was precipitated by 
adding acetone (ten times the volume of mixture) and centrifuged (8,608 × g, 30 min) 
to remove unreacted AA. The precipitation step was repeated three times. Next, the 
precipitate was dispersed with DDW and dialyzed with dialysis membrane 
(molecular weight cut-off = 1 kDa; Spectrum Laboratories, Laguna Hills, CA, USA) 
against DDW for 24 h. The dialyzed products were lyophilized. 
The conjugation of CSOAA was confirmed by Fourier transform infrared 
spectroscopy (FTIR) and 1H–nuclear magnetic resonance (NMR) analyses. FTIR 
spectra were obtained with a JASCO FTIR 4200 spectrometer (JASCO Company 
Ltd., Hachioji, Japan) by KBr method. The 1H-NMR spectra were obtained using a 
Varian FT500-MHz NMR spectrometer (Varian Inc., Palo Alto, CA, USA). Samples 
(15 mg/ml) were dissolved in DMSO-d6. The molar substitution (MS) of CSOAA, 
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which is total number of moles of reacted AA per one mole of CSO, was determined 
by integration of the values of the proton peaks from the 1H-NMR spectra. MS of 
CSOAA was obtained using a linear regression line generated from standard samples 
with various molar ratios between AA and CSO (0.5:1, 1:1, 2:1, 3:1, and 4:1). The 
standard samples were prepared by homogeneously mixing CSO and AA in 
DDW/tetrahydrofuran (THF) mixture (1:1, v/v). THF was removed by evaporation 
and the resultant was lyophilized. The ratio of integration are a (1.23/1.81 ppm) of 
each standard sample was calculated. 
 
2.3. Preparation and characterization of nanoparticles 
 
To investigate the self-assembly behavior of CSOAA, the critical micelle 
concentration (CMC) of CSOAA was determined by using pyrene as a fluorescence 
probe. The fluorescence emission spectrum of pyrene (6 × 10-7 M) was recorded at 
360–450 nm in the CSOAA concentration range from 10-4 to 1 mg/ml. The excitation 
wavelength was 334 nm and the slit openings for excitation and emission were set at 
10 and 3 nm, respectively. The intensity ratio of the first peak (I1, 373 nm) to the 
third peak (I3, 384 nm) was calculated to determine the CMC. 
Blank (without drug loading) self-assembled nanoparticles were prepared by 
dissolving CSOAA in DDW, vortexing for 15 min, and filtering through a 0.2-µm 




DOX base was used as a hydrophobic drug and encapsulated into the CSOAA 
nanoparticles by a solvent evaporation method. To prepare DOX base according to 
a reported method (Cho et al., 2012b), DOX HCl was reacted with triethylamine in 
DMSO for 12 h, and then lyophilized. To make DOX-loaded nanoparticle, DOX 
base (1 mg) was dissolved in 1 ml DMSO and DDW mixture (1:1 v/v). CSOAA (7.5 
mg) was added to that mixture and vortexed for 10 min. The solvent was evaporated 
under a nitrogen gas stream for 4 h at 70°C. DOX-loaded CSOAA-based self-
assembled nanoparticles were obtained by resuspending the polymer and drug 
composite film with 1 ml DDW. That suspension was gently stirred for 15 min and 
further heated at 70°C for 15 min. Unloaded drug was eliminated with a 0.22-µm 
syringe filter. 
Encapsulation efficiency (EE) of the DOX in nanoparticles was determined by 
disrupting DOX-loaded nanoparticles with 100× the volume of DMSO. DOX was 
analyzed quantitatively by Waters high-performance liquid chromatography (HPLC) 
system (Waters Co., Milford, MA, USA), equipped with a reversed-phase C-18 
column (Xbridge RP18, 250 × 4.6 mm, 5 μm; Waters Co.), a separation module 
(Waters e2695), and a fluorescence detector (Waters 2475). The mobile phase 
consisted of 0.1 M sodium acetate buffer (pH 4.0, adjusted with acetic acid) and 
acetonitrile (71:29 v/v), and the eluent was monitored at excitation and emission 
wavelengths of 470 nm and 565 nm, respectively, with a flow rate of 1.0 ml/min. 
The injection volume for drug analysis was 20 µl. The EE value was calculated using 
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the following equation: 
         
         (1) 
 
Mean diameter and zeta potential values of the blank nanoparticles and DOX-
loaded nanoparticles were measured by a dynamic light scattering (DLS) method 
(ELS-Z, Photal; Otsuka Electronics Co. Ltd., Osaka, Japan). The morphological 
shapes of self-assembled nanoparticles were observed under transmission electron 
microscopy (TEM; LIBRA 120; Carl Zeiss, Oberkochen, Germany). The samples 
were placed on a copper grid coated with carbon film, dried at 20°C, and 
photographed. 
 
2.4. In vitro DOX release 
 
In vitro release studies were performed in phosphate-buffered saline (PBS; pH 
5.5, 6.8, and 7.4, adjusted with phosphoric acid) at 37°C. DOX-loaded CSOAA-
based nanoparticles (150 μl) were placed in a mini GeBA-flex tube (molecular 
weight cut-off = 12–14 kDa). That tube was then transferred to 10 ml release medium 
and kept in the horizontal shaker at 37°C and 50 rpm of rotation speed. An aliquot 
(0.2 ml) of the release medium was periodically collected (at 1, 2, 3, 4, 6, 9, 12, 24, 
48, 72, 96, 120, and 144 h) and the same volume of fresh medium was replaced. The 
released DOX was quantitatively analyzed by HPLC system. 
100
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2.5. In vitro cytotoxicity of CSOAA 
 
FaDu cells were purchased from the Korean Cell Line Bank (Seoul, Korea). 
These cells were cultured in MEM containing 10% FBS, 100 U/ml penicillin, and 
100 µg/ml streptomycin at 37°C under 5% CO2 atmosphere and 95% relative 
humidity. The cytotoxicity of CSOAA was determined by a 3-(4,5-dimethylthiazol-
2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H- tetrazolium (MTS)-based 
assay. Cells were seeded in 96-well plates at a density of 1.0 × 104 cells per well. 
After 24 h of incubation, the cell culture medium was replaced with 200 µl medium 
containing various concentrations (5–500 µg/ml) of CSOAA and incubated for 12 
and 24 h. After discarding the culture medium, cells were treated with the MTS-
based Cell Titer 96 AQueous One Solution Cell Proliferation Assay Reagent (Promega 
Corp., Madison, WI, USA) at 37°C for 4 h, according to the manufacturer's protocol. 
The spectrophotometric absorbance of samples were measured at a wavelength of 
490 nm using an EMax Precision Microplate Reader (Molecular Devices, Sunnyvale, 
CA, USA). 
 
2.6. In vitro cellular uptake 
 
Cellular uptake efficiency was evaluated by flow cytometry analysis. FaDu cells 
were seeded in 6-well plates at a density of 6 × 105 cells per well and grown overnight 
10 
 
at 37°C. The culture medium was then removed, and the cells were incubated with 
free DOX or the DOX-loaded CSOAA-based nanoparticles at an equivalent DOX 
concentration (50 μg/ml) for 1 h. After washing with PBS (pH 7.4) at least three 
times, the cells were detached and centrifuged. The supernatant was then removed 
and the cell pellets were resuspended with PBS containing 2% (v/v) FBS. DOX 
uptake was analyzed using a Calibur fluorescence-activated cell sorter equipped with 
CELLQuest software (Becton Dickinson Biosciences, San Jose, CA, USA). 
 
2.7. In vivo anti-tumor efficacy 
 
Female BALB/c nude mice (5 weeks old; Charles River) were used to prepare 
a tumor-bearing mouse model for evaluating anti-cancer efficacy. Mice were 
maintained in a light-controlled room kept at a temperature of 22 ± 2°C and a relative 
humidity of 55 ± 5% (Animal Center for Pharmaceutical Research, College of 
Pharmacy, Seoul National University, Seoul, Korea). Experimental protocols used 
were approved by the Animal Care and Use Committee of the College of Pharmacy, 
Seoul National University. BALB/c nude mice bearing FaDu tumors were prepared 
by subcutaneous injection of 3 × 106 cells at the right back of mice. Tumor size was 
measured with Verniercalipers and tumor volume (mm3) was calculated according 
to the following formula: volume = 0.5 × longest diameter × shortest diameter2. 
Measuring tumor volume and weighing body weight started 10 days post-inoculation, 
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when the tumor volume reached about 50–100 mm3. The mice were divided into 
three groups: control, DOX solution, and DOX-loaded CSOAA-based nanoparticles. 
Both DOX solution and DOX-loaded nanoparticles were injected intravenously at a 
dose of 2.5 mg/kg on days 6, 8, 11, and 13. The tumor volume and body weight were 
monitored for 18 days. 
 
2.8. Statistical analysis 
 
Statistical analyses were performed using analysis of variance. All experiments 





3.1. Synthesis and characterization of CSOAA 
 
 The CSOAA conjugate was synthesized by EDC- and NHS-mediated amide 
bond formation between the carboxylic group of AA and the amine group of CSO. 
The synthesis scheme is shown in Fig. 1. EDC can react with the carboxylic group 
of AA to form an EDC active ester, and the NHS ester intermediate forms rapidly. 




 The structural characterization of CSOAA was performed using FTIR and 1H-
NMR. The FTIR spectrum (Fig. 2) confirmed the synthesis of the CSOAA conjugate. 
Absorption bands of CSO at 1591 and 1643 cm-1 were assigned to N-H bending of 
the deacetylated amine (-NH2) and carbonyl stretching of a non-deacetylated amide 
(NHC=OCH3; amide I band), respectively. After the reaction, the amine peak at 1591 
cm-1 of CSO disappeared and a new absorption band at 1558 cm-1 in the spectrum of 
CSOAA was observed, which was associated with the formation of a new amide 
bond (amide II band). Additionally, absorption bands at 2918 and 2851 cm-1 of 
CSOAA represented stretching vibrations of the acyl chain, -CH2- and –CH3 of AA, 
respectively. The conjugation of AA to CSO was also confirmed by 1H-NMR 
analysis (Fig.3). The 1H-NMR spectrum of CSOAA exhibited proton signals for both 
CSO and AA. Although the proton peaks of the glucosamine ring of CSO at 3–4 
ppm overlapped with the DMSO-d6 solvent, the proton peaks at 0.86 and 1.23 ppm 
indicated a terminal methyl group (-CH3) and an alkyl chain (-CH2-) of AA, 
respectively. Furthermore, the proton peak of –CH2-, which links with carbonyl 
group of unconjugated AA, was present at 2.21 ppm. This proton peak shifted to 
2.07 ppm after the carboxylic group of AA was conjugated to the amine group of 
CSO. In addition, the new proton peak was absent in the spectrum of a physical 
mixture of CSO and AA (Fig. 4). This result indicated that AA was successfully 
conjugated to the CSO backbone via amide bond formation.  
 To calculate the MS of CSOAA, the homogeneous physical mixtures of CSO 
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and AA (at different molar ratios) were prepared as standard samples and analyzed 
by 1H-NMR. As shown in Fig. 5, the linear regression line was generated by plotting 
the ratio of integration area between peak of the alkyl chain protons of AA (δ = 1.23 
ppm; -CH2-) and the N-acetyl protons of CSO (δ=1.81 ppm; NH-CO-CH3) according 
to the molar ratio of AA/CSO. The MS of CSOAA was 1.00 (mole of AA/mole of 
CSO), calculated from the equation of regression line with its 1H-NMR integration 
ratio (1.23/1.81ppm), when the initial molar ratio (AA/CSO) was 3 in the 
conjugation reaction. The chemical yield of CSOAA was 61.2%. 
The self-assembly behavior of CSOAA in the aqueous phase was investigated 
by fluorescence measurements, using pyrene as a fluorescence probe (Fig. 6). CMC 
can be determined by measuring the intensity ratio (I1/I3) between the first (373 nm) 
and third (384 nm) emission peaks of pyrene according to the CSOAA concentration. 
As shown in Fig. 6, the CMC of CSOAA was 1.42 µg/ml. 
 
3.2. Preparation and characterization of CSOAA-based self-
assembled nanoparticles 
 
Blank self-assembled nanoparticles were prepared by dissolving CSOAA in the 
aqueous solution. The formation of nanoparticles was confirmed by measuring 
particle size and zeta potential values. To load DOX into the CSOAA-based 
nanoparticles (Fig. 7), a solvent evaporation method was used. The mean diameter 
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and zeta potential values were measured by DLS and are shown in Table 1. The mean 
diameter of blank nanoparticles was smaller than that of DOX-loaded nanoparticles 
(73.67 ± 3.91 nm vs. 130.00 ± 5.76 nm). The polydispersity index of the DOX-loaded 
nanoparticles was 0.23 ± 0.02, indicating a narrow size distribution of nanoparticles 
(Fig. 8a). The zeta potential value was also increased slightly after loading DOX into 
the nanoparticles (from 7.58 ± 0.62 mV to 12.98 ± 0.55 mV). The spherical shape of 
the DOX-loaded CSOAA-based nanoparticles was observed by TEM (Fig. 8b). No 
aggregation of CSOAA-based nanoparticles was observed in that image. The loading 
amount of DOX in the nanoparticles was measured by HPLC analysis and the EE 
was 53.12 ± 2.60%. 
 
3.3. In vitro DOX release 
 
DOX release patterns from nanoparticles were investigated under different pH 
conditions (pH 5.5, 6.8 and 7.4) at 37°C (Fig. 9). DOX release from the CSOAA-
based nanoparticles was monitored for 6 days. Sustained drug release was observed 
and it was dependent on the pH of the release medium. About 30% of DOX was 
released in the first 12 h under all pH conditions. After that, the amounts of DOX 
released from CSOAA-based nanoparticles increased as the pH value of the releasing 
medium decreased. After 6 days, DOX was completely released at pH 5.5; in contrast, 
78% and 64% of DOX was released at pH 6.8 and 7.4, respectively. 
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3.4. In vitro cytotoxicity test 
 
To examine the cytotoxicity of CSOAA, cell viability was measured in FaDu 
cells, a head and neck cancer cell line. The cells were treated with various 
concentrations of CSOAA for 12 and 24 h. As shown in Fig. 10, FaDu cell viability 
(%) was over 90% for all CSOAA concentrations tested. Thus, it can be concluded 
that CSOAA had no severe toxicity for FaDu cells. 
 
3.5. In vitro cellular uptake study 
 
The cellular uptake efficiency of DOX in FaDu cells was investigated by flow 
cytometry. Fluorescence intensity was assumed to be proportional to the amount of 
DOX internalized into the cells. Fig. 11 shows that higher amount of DOX from 
CSOAA-based nanoparticles was taken up into the cells than from the DOX solution 
group. 
 
3.6. In vivo anti-tumor efficacy 
 
In vivo anti-tumor efficacy of DOX-loaded nanoparticles was assessed in a 
FaDu tumor- bearing mouse model. DOX solution and DOX-loaded CSOAA-based 
nanoparticles were injected intravenously on days 6, 8, 11, and 13. Tumor volume 
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(mm3) and body weight (g) were monitored for 18 days. As shown in Fig. 12a, tumor 
growth inhibition in the DOX-loaded nanoparticle-treated group was significantly 
higher than in either the DOX solution–treated group or the control group (p < 0.05). 
After 18 days of treatment with DOX solution or DOX-loaded nanoparticles, tumor 
volumes were 44.63 ± 9.02% and 25.24 ± 5.61% of that for control group. No 
significant difference in body weight change was observed among the three groups; 




In this study, CSOAA was successfully synthesized as a hydrophobically 
modified CSO for the preparation of self-assembled nanoparticles. The synthesis of 
CSOAA conjugate was confirmed by 1H-NMR analysis, but accurate substitution 
ratio (AA to CSO) might not be obtained from 1H-NMR spectrum of CSOAA. From 
1H-NMR analysis of CSOAA, the proton peak of the glucosamine ring of CSO could 
be overlapped with the solvent peak and deacetylation degree of CSO was not 
obviously determined. Because of these limitations, the correlation between the 
integration ratio (1.23/1.81 ppm) and molar ratio of AA/CSO, based on physical 
mixture, was evaluated in this investigation (Fig. 5). With the input of the integration 
ratio (1.23/1.81 ppm) for CSOAA conjugate into this regression line, the 
stoichiometry of CSOAA can be determined more accurately. It is assumed that 
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established assay (Fig. 5) could help identify the synthesis of CSOAA and calculate 
substitution ratio. The CMC value is also an important characteristic of micellar 
structured nanoparticle. The CMC value of CSOAA was significantly lower than 
those of low-molecular-weight surfactants in water (Lee et al., 1998). It can be 
concluded that CSOAA can form stable nanoparticulate structures at its low 
concentration after dilution with a large volume of body fluids. 
The CSOAA synthesized could readily produce self-assembled nanoparticles in 
aqueous solution because of its amphiphilic property. The AA part could constitute 
an internal hydrophobic core, while CSO could provide a hydrophilic outer shell of 
the nanoparticles. The DOX-loaded CSOAA-based self-assembled nanoparticles 
were prepared by a solvent evaporation method. This method can provide several 
advantages over dialysis methods, such as the short preparation period and high drug 
loading efficiency (Park et al., 2004). DOX-loaded CSOAA-based nanoparticles 
exhibited <200 nm of mean diameter and narrow size distribution, high drug 
encapsulation efficiency, and negligible cytotoxicity. Because of these properties, it 
is assumed that DOX-loaded CSOAA-based nanoparticles can effectively 
accumulate in the tumor region via the EPR effect and exhibit reduced uptake by 
RES (Maeda et al., 2000; Yuan et al., 1995). 
The sustained and pH-dependent drug release patterns from the CSOAA-based 
nanoparticles developed were observed (Fig. 8). Sustained drug release can lead to 
reduce in vivo drug clearance and maintenance of effective drug concentrations for 
tumor growth inhibition. Additionally, larger amount of DOX was released at acidic 
18 
 
pH, simulating the endocytic compartment of cancer cells, compared with normal 
pH condition (pH 7.4). This difference may have been due to the slack structure of 
the nanoparticle, following protonation of amino groups in CSO and the higher 
solubility of DOX at an acidic pH. These results indicate that DOX-loaded CSOAA-
based nanoparticles can be highly accumulated and release a large amount of drug 
in tumor tissues, with less DOX delivery to non-tumor regions. Moreover, enhanced 
drug release at pH 5.5 can imply endosomal escape of the drug and its improved 
transport to the cell nucleus. 
As shown in Fig. 11, larger amount of DOX from nanoparticle-treated group 
was taken up to the cells compared to that from DOX solution group. This result may 
be explained by the interaction between the positively charged surface of the 
CSOAA-based nanoparticle and the negatively charged cellular membrane, and 
subsequent endocytosis of nanoparticles (Chavanpatil et al., 2006; Lee et al., 2011; 
Zauner et al., 1998). Furthermore, fatty acid–modified CS nanoparticles have been 
reported to form self-assembled nanoparticles with a multi-hydrophobic core (You 
et al., 2007). A hydrophobic minor core may help the internalization of nanoparticles 
into the cells by inserting fatty acids into the cell membrane. 
FaDu cells were selected as a head and neck cancer cell line for this 
investigation. As shown in Fig. 12a, DOX-loaded CSOAA-based nanoparticles 
exhibited significant inhibitory effects on FaDu tumor growth, compared with both 
the control and DOX solution–treated groups. The physiochemical properties of 
drug-loaded nanoparticles, sustained drug release, and passive targeting, via mainly 
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an EPR effect, may explain the efficient tumor growth inhibition by DOX-loaded 
CSOAA-based nanoparticles. In conclusion, the self-assembled CSOAA-based 
nanoparticle developed can be used as an anti-cancer drug delivery system, 




 CSOAA was synthesized for the preparation of self-assembled nanoparticles 
for DOX delivery. Its CMC value was relatively low and it could form self-
assembled nanoparticles in an aqueous environment with a narrow size distribution. 
DOX-loaded CSOAA-based nanoparticles showed a sustained and pH-dependent 
drug release profile. It seemed that the nanoparticulate structure and drug release 
profile of the nanoparticles influenced on the cellular uptake and anti-tumor activity. 
DOX-loaded CSOAA-based nanoparticles significantly inhibited FaDu tumor 
growth in vivo. Considering all of experimental results in this study, CSOAA-based 
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Figure 5 The correlationship between the ratio of integration area (1.23/1.81 ppm) 
and molar ratio of AA/CSO based on their physical mixture. Each point represents 

















Figure 6 CMC determination of CSOAA. Fluorescence intensity ratio (I373/I384) was 


































Figure 8 Size distribution and morphology of DOX-loaded CSOAA-based 
nanoparticles. (a) Size distribution of DOX-loaded CSOAA-based nanoparticles is 
determined by dynamic light scattering (DLS). The weight ratio between CSOAA 
and DOX was 7.5 to 1. (b) TEM images of DOX-loaded CSOAA-based 











Figure 9 In vitro DOX release profiles of CSOAA-based self-assembled 
nanoparticles. Drug release profiles from CSOAA: DOX = 7.5:1 formulation at 
different pH conditions (pH 5.5, 6.8 and 7.4) were shown. Each point represents 


















Figure 10 In vitro cytotoxicity tests of CSOAA in FaDu cells. Various 
concentrations of CSOAA were incubated for 12 and 24 h. Cell viability was 









Figure 11 Cellular uptake efficiency of DOX was analyzed by flow cytometer. DOX 
solution and DOX-loaded nanoparticles were incubated for 1 h. Various colors 
indicate each experimental group (black: control, red: DOX solution, green: DOX-












Figure 12 Anti-tumor efficacy test of DOX-loaded CSOAA-based nanoparticles in 
a FaDu tumor bearing BALB/c nude mouse model. (a) Tumor volume (mm3) profiles 
according to the time (days) for 18 days are shown. DOX solution and DOX-loaded 
nanoparticles were injected intravenously on days 6, 8, 11, and 13. (b) Body weight 
(g) was monitored. Each point indicates mean ± S.D (n≥4). *P < 0.05 vs. control 





PART II. Self-assembled magnetic resonance imaging 






 Alongside innovations in drug delivery for cancer therapy, imaging techniques 
for cancer diagnosis have also evolved. Progress in imaging agents and apparatus 
used for magnetic resonance imaging (MRI), computed tomography (CT), positron 
emission tomography (PET), single-photon emission computed tomography 
(SPECT) and ultrasound have contributed to more accurate diagnosis of cancer. MRI 
is one of the most powerful imaging techniques for diagnosis and has several 
advantages, such as high resolution of specific tissues and organs and deep 
penetration into the soft tissues (Janib et al., 2010; Liu et al., 2012; Villaraza et al., 
2010). MRI can provide abundant information on the anatomical and physiological 
state of the body (Cho et al., 2012b). Additionally, contrast agents are used to 
improve sensitivity resulting from the interaction with surrounding water protons 
and shortening of the proton relaxation time to enhance contrast (Johnson et al., 
2011). Contrast agents can be classified into the T1-weighted type (paramagnetic 
gadolinium chelates) and the T2-weighted type (superparamagnetic iron oxide 
nanoparticles; SPION), which could enhance the contrast of regions of interest 
positively or negatively, respectively (Liu et al., 2012; Villaraza et al., 2010). In 
particular, the T1 contrast agents (paramagnetic Gd3+ chelates) have several 
advantages: high magnetic moment, suitable electron relaxation time, and a positive 
contrast enhancing effect (Liu et al., 2012; Caravan et al., 1999). Clinically relevant 
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Gd3+ chelates are as follows (Caravan et al., 1999) Gd-diethylenetriaminepentaacetic 
acid (Gd-DTPA), Gd-1,4,7,10-tetra- azacyclododecane-1,4,7,10-tetraacetic acid 
(Gd-DOTA), and Gd-10- (2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triacetic acid (Gd-HP- DO3A). Although these Gd3+ chelates have been used 
successfully clinically, they have some problems; reduction of relaxivity (r1) by 
chelation (mainly due to the decreased number of coordination sites for water proton 
exchange), lack of specificity for certain tissues or organs, and rapid clearance from 
the blood due to renal excretion (Ananta et al., 2010; Kobayashi et al., 2001). 
Therefore, acquisition of enough spatial information on long-term application and 
disease targeting is difficult. It is expected that development of polymeric 
nanoparticles-based imaging agents will solve these problems. Recently, 
polysaccharide-based nanoprobes for MR imaging have been investigated (Cho et 
al., 2012b; Ernsting et al., 2012; Lim et al. 2011; Yim et al., 2011). Various MR 
imaging probes based on chitosan or its derivatives have been developed (Cheng et 
al., 2012; Key et al., 2012; Yuk et al., 2011). Pure chitosan does not include any 
tumor-targeting ligand for cancer diagnosis, but chitosan nanoparticles can 
accumulate in the tumor region after intravenous injection, mainly due to the 
enhanced permeability and retention (EPR) effect. In our previous study 
(Termsarasab et al., 2013), chitosan oligosaccharide–arachidic acid (CSOAA), as an 
amphiphilic CSO derivative, was synthesized and used to prepare self-assembled 
nanoparticles. A hydrophobic anti-cancer drug was incorporated into the 
hydrophobic internal cavity of nanoparticles and injected intravenously into a head 
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and neck cancer xenografted mouse model to evaluate in vivo anti-tumor efficacy. 
Herein, we report the development and in vitro evaluation of CSOAA-DTPA-Gd 
nanoprobes for MR imaging of cancer. DTPA was conjugated to CSO, after which 
Gd3+ was chelated to the DTPA ligand. It is expected that self-assembled CSOAA 
can form a nano-sized MRI probe (mean diameter, ∼150 nm) in an aqueous 
environment, and thus can act as a useful MR imaging probe for cancer diagnosis. 
 




 Chitosan oligosaccharide (average molecular weight = 5 kDa, degree of 
deacetylation >90%) was purchased from Kitto Life Co., Ltd. (Seoul, Korea). 
Arachidic acid (AA), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), N-
hydroxysuccinimide (NHS), pyrene, diethylenetriaminepentaacetic dianhydride 
(DTPA), and gadolinium (III) chloride hexahydrate (GdCl3 •6H2O) were purchased 
from Sigma Chemical Co. (St. Louis, MO, USA). Cy5.5 NHS ester was purchased 
from Amersham Biosciences (Piscataway, NJ, USA). Dulbecco’s modified 
Eagle’s medium (DMEM), minimum essential medium (MEM), penicillin, 
streptomycin, and heat-inactivated fetal bovine serum (FBS) were obtained from 
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Gibco Life Technologies, Inc. (Grand Island, NY, USA). All other chemicals were 
of reagent grade and used without further purification. 
 
2.2. Synthesis of CSOAA-DTPA-Gd 
 
CSOAA was synthesized according to our previous method (Termsarasab et al., 
2013). In brief, CSO (0.2 mmol) and AA (0.6 mmol) were dissolved separately in 20 
ml dimethyl sulfoxide (DMSO) at 50 ◦C for 15 min. The carboxyl groups of AA 
were activated by adding EDC and NHS (molar ratio for AA = 1.5:1) and stirring 
for 30 min at room temperature. The activated AA solutions were added to the CSO 
solution for 5 min, then allowed to react for a further 12 h, after which double 
distilled water (DDW) at a volume ratio of 10% was added. The pH of mixed 
solutions was adjusted to 3.5 with 1 N HCl and stirred for 30 min. The solution was 
precipitated with acetone (ten times the volume of the mixture, v/v) and centrifuged 
at 7500 rpm for 30 min to eliminate unreacted AA. The precipitation step was 
repeated three times. After precipitation, the precipitates were dispersed with DDW 
and dialyzed against DDW with a dialysis membrane (molecular weight cut-off: 1 
kDa, Spectrum Laboratories, Laguna Hills, CA, USA) for 1 day. Dialysis products 
were obtained by freeze drying. DTPA was conjugated to CSO by amide bond 
formation between the carboxylic group of DTPA and the amine group of CSO. 
DTPA (0.1 mmol) was dissolved in DDW (15 ml), and EDC (0.2 mmol) and NHS 
(0.2 mmol) were added. After stirring for 30 min, the solution was slowly added to 
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CSOAA (0.02 mmol) solution in DDW (20 ml). It was further stirred for 12 h at 
room temperature and dialyzed with a dialysis membrane (molecular weight cut-off: 
3.5 kDa) against DDW for 3 days. CSOAA-DTPA was obtained by lyophilization. 
For Gd3+ chelation, GdCl3 •6H2O (0.05 mmol) dissolved in 5 ml of DDW was slowly 
added to CSOAA-DTPA (0.01 mmol) dissolved in 30 ml DDW and the pH was 
adjusted to 7 by 1 N NaOH. It was stirred for 24 h and dialyzed for 3 days against 
DDW to remove free Gd3+. CSOAA-DTPA-Gd was obtained by freeze-drying. 
DTPA conjugation to CSOAA was identified by 1H NMR analysis (500 MHz). 
CSOAA-DTPA was solubilized in deuterium oxide (D2O) for 1H NMR analysis. 
DTPA conjugation and Gd3+ chelation were also confirmed by FT-IR analysis with 
a JASCO FT-IR 4200 spectrometer (JASCO Company Ltd., Hachioji, Japan). Gd 
content in the CSOAA-based nanoprobe was determined by an inductive coupled 
plasma-atomic emission spectrometer (ICP-AES, Optima 4300 DV, Perkin Elmer 
Inc., Wellesley, MA, USA). 
 
2.3. Characteristics of the CSOAA-based nanoprobe 
 
To produce CSOAA-based nanoprobes, CSOAA-DTPA-Gd was solubilized in 
DDW, phosphate buffered saline (PBS, pH 7.4) or 50% (v/v) FBS solution (in PBS 
pH 7.4). After dissolving at a predetermined concentration, the sample was sonicated 
using a probe-type sonicator (Vibra-Cell VC 750 ultrasonic processor, Sonics & 
Materials, CT, USA) for 1 min. Mean diameter, polydispersity index, and zeta 
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potential values of the nano-sized probe were measured using a light scattering 
spectrophotometer (ELS-Z; Otsuka Electronics, Tokyo, Japan) according to the 
manufacturer’s protocol. The morphology of the CSOAA-based nanoprobe was 
observed by transmission electron microscopy (TEM). The nanoprobes were placed 
on copper grids with films. After air-drying for 10 min, they were observed by TEM 
(JEM 1010; JEOL, Tokyo, Japan). The scale bar in the images represents 1 µm. 
Critical aggregation concentration (CAC) of the CSOAA-based nanoprobe was 
determined using a fluorescence spectrophotometer with pyrene as a hydrophobic 
substance. Pyrene dissolved in acetone (2×10−6 M) was prepared and 0.3 ml of that 
solution was transferred to each 1.5 ml tube. Acetone was evaporated under a gentle 
nitrogen (N2) gas stream for 1 h at 60°C. The nanoprobe solution in DDW (1 ml), 
the concentration of which ranged from 0.1–1000 µg/ml, was added to each tube to 
make a 6×10−7 M pyrene concentration. The emission spectrum (310–550 nm) was 
obtained at a fixed 334 nm excitation wavelength with a fluorescence spectrometer 
FP-6500 (JASCO Co., Tokyo, Japan). 
 
2.4. In vitro cytotoxicity of the nanoprobe 
 
Hep-2 and FaDu cells were purchased from Korean Cell Line Bank (KCLB, 
Seoul, Korea). Hep-2 cells were cultured with DMEM supplemented with 10% FBS, 
100 U/ml penicillin, and 100 µg/ml streptomycin, and FaDu cells were cultured with 
MEM containing 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin, in a 
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5% CO2 atmosphere with 95% relative humidity at 37°C. After Hep-2 and FaDu 
cells reached 70–80% confluency, they were trypsinized and seeded in a 96-well 
plate at a density of 1.0×104 per well. After incubation for 24 h, the culture medium 
was removed. After 12 and 24 h incubation of CSOAA-DTPA and CSOAA-DTPA-
Gd (15–300 µg/ml) with both cell types at 37 °C, 5% CO2 and 95% relative humidity, 
the cell viability (%) was determined using the MTS-based CellTiter 96 AQueous 
One Solution Cell Proliferation Assay Reagent (Promega Corp., WI, USA) at 37 °C 
for 4 h, according to the manufacturer’s protocol. The absorbance at 490 nm was 
measured using an Emax Precision Microplate Reader (Molecular Devices, 
Sunnyvale, CA, USA). 
 
2.5. In vitro cellular uptake 
 
To monitor the intracellular uptake of nanoprobes, Cy5.5, a near-infrared 
fluorescence (NIRF) dye for observation by confocal laser scanning microscopy 
(CLSM), was conjugated to a CSO backbone by amide bond formation. The 
CSOAA-DTPA conjugate (100 mg) was dissolved in 50 ml carbonate/bicarbonate 
buffer (50 mM, pH 9.6). Cy5.5 NHS ester (0.2 mg) dissolved in 0.02 ml DMSO was 
slowly added to a CSOAA-DTPA-containing buffer and stirred for 3 h at room 
temperature. Free Cy5.5 was removed by dialysis against DDW for 3 days. The final 
product was obtained by lyophilization. For Gd3+ chelation, the previously described 
synthesis method was used. In brief, GdCl3•6H2O (0.05 mmol) dissolved in 5 ml 
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DDW was slowly added to Cy5.5-CSOAA-DTPA (0.01 mmol) dissolved in 30 ml 
DDW and the pH was adjusted to 7 using 1 N NaOH. The solution was stirred for 
24 h and dialyzed for 3 days against DDW to remove free Gd3+. Cy5.5-CSOAA-
DTPA-Gd was obtained by freeze-drying. The Cy5.5 content in the Cy5.5-labeled 
CSOAA-based nanoprobe was determined by measuring absorbance at 650 nm with 
a UV/vis spectrophotometer (Emax Precision Microplate Reader, Molecular Devices, 
Sunnyvale, CA, USA). Linearity was established in the range 1–25 µg/ml Cy5.5. 
After Hep-2 and FaDu cells acquired 70–80% confluency, the cells were trypsinized 
and seeded onto culture slides (BD Falcon, Bedford, MA) at a density of 1.0×105 per 
well (surface area of 1.7 cm2 per well, four-chamber slides) and incubated for 24 h 
at 37 °C. The Cy5.5-labeled nanoprobe (1 mg/ml) was incubated for 0.5, 8 and 12 h 
at 37 °C. The cells were then washed with phosphate buffered saline (PBS, pH 7.4) 
at least three times and fixed with a 4% formaldehyde solution for 5 min. 
VECTASHIELD mounting medium with 4’,6-diamidino-2-phenylindole (DAPI) 
(H-1200; Vector Laboratories, Inc., Burlingame, CA, USA) was added to stain 
nuclei and prevent the fading of fluorescence. The preparations were observed by 








2.6. In vitro MRI study 
 
All MRI studies were performed with a 4.7-T MRI apparatus (Bruker BioSpec 
47/40, Karlsruhe, Germany). T1 contrast intensities of Gd-DTPA (Magnevist
®, Bayer 
Schering Pharma AG, Berlin, Germany) and the CSOAA-based nanoprobe were 
scanned at 5–100 µM Gd concentrations. Specific parameters were as follows: echo 
time (TE) = 6.5 ms, repetition time (TR) = 1000 ms, field of view (FOV) = 5 × 4 cm, 
matrix = 128 × 128, slice thickness = 2 mm. The proton relaxation enhancement can 











+ 𝑅1[𝑀]  (1) 
where (1/T1)obs and (1/ T1)d are the relaxation rates of the protons in the presence and 
absence of paramagnetic species (Gd), respectively, and [M] is the concentration of 
the paramagnetic species (Gd). 
 
2.7. Data analysis 
 
All experiments were performed at least three times and the data were 





3. Results and discussions 
 
3.1. Synthesis of the CSOAA-based nanoprobe 
 
CSOAA was synthesized, as an amphiphilic CSO derivative, to prepare self-
assembled nanoparticles according to the reported method (Termsarasab et al., 2013). 
CSOAA was synthesized by amide bond formation between the carboxylic group of 
AA and the amine bond of CSO by an EDC-coupled reaction (Fig. 1). Synthesis was 
identified by 1H-NMR analysis. Though the proton peaks for the glucosamine ring 
of CSO overlapped those of the solvent, the proton peaks at 0.86 and 1.23 ppm 
indicated that the terminal methyl group (-CH3) and alkyl chain (-CH2-) of AA were 
present (Termsarasab et al., 2013). In particular, the proton peak of CH2 of AA linked 
with the carbonyl group without conjugation (2.21 ppm) was shifted after amide 
bond formation (2.16 ppm). According to our previous report (Termsarasab et al., 
2013), conjugation of AA to the CSO backbone was also confirmed by FT-IR 
analysis. In particular, the amide II band was shifted from 1591 cm−1 in the CSO 
spectrum to 1558 cm−1 in the CSOAA spectrum. Prior to Gd chelation, DTPA was 
conjugated to CSOAA, as confirmed by 1H-NMR and FT-IR analysis. An amide 
bond was formed between the amine group of CSO and the carboxylic group of 
DTPA by an EDC coupled reaction (Fig. 1). As shown in Fig. 2, peaks indicating 
DTPA (3.3 ppm) and CSO (2.0 ppm) were presented in the 1H-NMR spectrum of 
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CSOAA-DTPA. The FT-IR spectra also revealed the conjugation of DTPA to 
CSOAA (Fig. 1B). The FT-IR spectrum of CSOAA was reported in our previous 
study (Termsarasab et al., 2013). Considering the FT-IR spectrum of CSOAA, the 
amide I band was shifted from 1648 cm−1 in the CSOAA spectrum to 1632 cm−1 in 
the CSOAA-DTPA spectrum (Fig. 3). In particular, the amide II band at 1558 cm−1 
in the spectrum of CSOAA was altered in the spectrum of CSOAA-DTPA. 
Absorption intensity of the C-O stretching band in CSOAA-DTPA at 1075 cm−1 was 
attenuated in the spectrum of CSOAA-DTPA-Gd by coordination of Gd3+ to DTPA. 
Furthermore, the Gd content in the CSOAA-based nanoprobe measured by ICP-AES 
was 5.43% (w/w). Synthesis of CSOAA-DTPA-Gd was also evaluated by 
measurement of zeta potential, as reported previously (Cho et al., 2012b; Yim et al., 
2011). As shown in Table 1, the zeta potential was decreased by DTPA conjugation 
from 12.50 ± 0.81 mV (CSOAA) to 9.21 ± 0.85 mV (CSOAA-DTPA). It may be 
induced by ionization of the carboxylic group of DTPA. After chelation of Gd3+ to 
CSOAA-DTPA, its zeta potential was slightly increased to 11.19 ± 0.39 mV. The 
zeta potential can be altered by several factors, such as nanoprobe concentration, 
DTPA conjugation degree, and Gd content.  
 
3.2. Characteristics of the nanoprobe 
 
A nano-sized CSOAA-based probe was prepared using the self-assembled 
property of CSOAA (Fig. 4). The mean diameter, polydispersity index, and zeta 
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potentials of the nanoprobe were measured. As shown in Table 1, the mean diameter 
of the CSOAA-DTPA-Gd nanoprobe was 146.30 ± 5.51 nm (at 1 mg/ml 
concentration of the nanoprobe) and was around 150 nm within 5 mg/ml 
concentration in DDW (Fig. 5A). Mean diameter of CSOAA-based nanoprobe (at 5 
mg/ml concentration) was 248.97 ± 6.70 and 167.70 ± 0.92 nm in 50% (v/v) FBS 
solution (in PBS pH 7.4) and PBS (pH 7.4), respectively (Fig. 5B). The mean 
diameters of nanoprobe in both media were maintained constantly for 4 h. Although 
the particle size of nanoprobe in 50% FBS solution slightly increased compared to 
that in DDW or PBS, it is still considered to be suitable for the cellular uptake and 
passive tumor targeting. The morphology was observed by TEM to be spherical (Fig. 
6A). The CSOAA-based nanoprobe also exhibited a narrow size distribution (Fig. 
2B). The CAC value of CSOAA was 1.42 µg/ml (Termsarasab et al., 2013) and that 
of CSOAA-DTPA-Gd was 3.86 µg/ml (Fig. 7); the lower value implies that the 
CSOAA-based nanoprobe may be more stable after dilution in body fluids. Gd-
DTPA (Magnevist) has a terminal elimination half-life of about 20 min (Weinmann 
et al., 1984). Considering the higher molecular weight and larger particle size of the 
developed polymeric nanoprobe, a polymeric nanoprobe including Gd-DTPA likely 
exhibits reduced in vivo clearance, thereby increasing its blood circulation time 
compared to the commercial contrast agent (Magnevist). Moreover, the EPR effect 
can improve accumulation of nanoprobes in the tumor region. In our previous report, 
the nano-sized polymeric probe exhibited MR signal-enhancing effects in the tumor 
region compared to the commercial formulation (Cho et al., 2012b). The particle size 
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(∼150 nm) of the experimental nanoprobe in this study may yield improved tumor 
targetibility and cancer diagnosis. 
 
3.3. In vitro cytotoxicity 
 
The cytotoxicity of the CSOAA-based nanoprobe (CSOAA-DTPA and 
CSOAA-DTPA-Gd) was evaluated in cancer cells according to nanoprobe 
concentration and incubation time. In this investigation, Human laryngeal and 
pharyngeal cancer (Hep-2 and FaDu) cells were used. These two cell types have 
previously been used for head and neck cancer research (Cho et al., 2012a; 
Termsarasab et al., 2013). CSOAA showed no severe cytotoxicity in FaDu cells in a 
previous report (Termsarasab et al., 2013); therefore, its cytotoxicity was not 
evaluated in this study. Viability (%) in both cell types was assessed by MTS-based 
assay. As shown in Fig. 8, the cytotoxicity of CSOAA-DTPA and CSOAA-DTPA-
Gd seemed to be inconsequential in both cell lines at the probe concentrations and 
incubation times (12 and 24 h) used. Although Gd has been used as a representative 
T1-weighted contrast agent, the aqueous Gd3+ ion exhibited severe cytotoxicity 
(Ananta et al., 2010). Therefore, organic linear and macrocyclic ligands (e.g. DTPA) 
are required to chelate Gd3+ to reduce toxicity (Ananta et al., 2010; Bartolini et al., 
2003). CSOAA-DTPA-Gd exhibited no severe cytotoxicity in head and neck cancer 




3.4. In vitro cellular uptake 
 
The cellular uptake efficiency of the experimental nanoprobe was determined 
by CLSM. The nanoprobe was labeled with Cy5.5 and its intracellular uptake and 
distribution were observed. Cy5.5 was used as a NIRF imaging dye for in vivo tumor 
imaging in our previous studies (Cho et al., 2012b; Cho et al., 2011; Cho et al., 
2012c). The Cy5.5 NHS ester was conjugated to the amine group of CSO by amide 
bond formation; the Cy5.5 content of the Cy5.5-labeled CSOAA-based nanoprobe 
was 0.13% (w/w). Cellular uptake and distribution patterns of Cy5.5-labeled 
nanoprobe were monitored up to 12 h in both Hep-2 and FaDu cells. The Cy5.5 
fluorescence intensity, indicating the amount of nanoprobe taken up by cells, 
increased according to incubation time in both cell types (Fig. 9). 
The physicochemical properties of nanoparticles, such as mean diameter, 
surface charge, morphology and composition, can influence their cellular uptake and 
distribution (Chavanpatil et al., 2006). Though smaller nanoparticles with a uniform 
size distribution exhibit increased uptake, other factors can play important roles in 
cellular uptake of chitosan-based nanoparticles (Desai et al., 1996; Kim et al., 2001; 
Nam et al., 2009). The surface charge of a nanoparticle can affect its cellular uptake 
and subsequent cellular distribution. Electrostatic interaction between positively 
charged chitosan-based nanoparticles and the negatively charged cellular membrane 
can facilitate cellular binding and uptake of nanoparticles. The positive charge of a 
chitosan-based nanoparticle promoted its internalization rate and level in eight cell 
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lines (Yue et al., 2011). In addition, some positively charged nanoparticles escaped 
the lysosome and localized perinuclearly. Endocytosis of the nanoprobe is thought 
to be governed by its particle size (∼150 nm) and positive zeta potential (Table 1). 
 
3.5. Phantom study 
 
In vitro paramagnetism of Gd-DTPA (Magnevist) and CSOAA-DTPA-Gd were 
evaluated by 4.7-T MRI. In Fig. 10A, T1-weighted MR images of both formulations 
according to the Gd concentration (5–100 µM) are shown. As Gd concentration 
increased, MR signals were also enhanced, as indicated by the brightness in both 
groups. The MR signals were analyzed quantitatively and a linear relationship 
between the proton longitudinal relaxation rate (1/T1) and Gd concentration was 
identified. T1 relaxivity (r1) was calculated using Eq. (1). T1 relaxivity of the 
CSOAA-based nanoprobe was 15.28 mM−1s−1, 2.43-fold higher than that of Gd-
DTPA (Magnevist) in this investigation (Fig. 10B). In our previous report (Cho et 
al., 2012b), a contrast enhancing effect of a hyaluronic acid derivative-based 
nanoprobe compared to the commercial formulation (Magnevist) was found. 
CSOAA also has several hydroxyl groups in its glucose ring unit that can attract 
adjacent water molecules, thereby improving the local density of water molecules 
(Cho et al., 2012b). This may increase the water exchange rate in Gd molecules and 
lead to enhanced T1 relaxivity (Yim et al., 2011; Caraban, 2006). 
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Although therapeutic drugs were not incorporated in this study, the formation 
of an internal hydrophobic core due to the AA segment is expected to facilitate 
loading of hydrophobic drugs. Anti-cancer drug delivery using an unmodified 
CSOAA nanoparticle and its anti-tumor efficacy in a head and neck cancer model 
have been reported previously (Termsarasab et al., 2013). Therefore, although it is 
expected that the theranostic nanoparticle based on CSOAA is feasible for cancer 




Self-assembled CSOAA-based nanoprobes including a T1 contrast agent was 
developed for MR imaging. DTPA was conjugated to CSOAA via an amide bond 
and Gd3+ was chelated to the DTPA ligand. This created a spherical nanoprobe of 
∼150 nm mean diameter with a positive zeta potential. The CSOAA-based 
nanoprobe exhibited negligible cytotoxicity in head and neck cancer cell lines. 
Cellular uptake and distribution of the Cy5.5-labeled nanoprobe were also observed 
by CLSM and the amount of nanoprobe taken up in head and neck cancer cells 
increased according to incubation time. The T1 contrast-enhancing effect of the 
CSOAA-based nanoprobe, compared to the commercial formulation (Magnevist), 
was demonstrated in a phantom study. These results suggest that the CSOAA-based 
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CSOAA 177.03 ± 2.75 0.20 ± 0.02 12.50 ± 0.81 
CSOAA-DTPA 177.90 ± 18.79 0.09 ± 0.01 9.21 ± 0.85 
CSOAA-DTPA-Gd 146.30 ± 5.51 0.20 ± 0.05 11.19 ± 0.39 
Value are presented as means ± standard deviation (SD) (n=3). 






















Figure 2 1H-NMR spectrum of CSOAA-DTPA. It was solubilized in D2O for 1H-













































in PBS (pH 7.4)











Figure 5 Characteristics of the CSOAA-based nanoprobe. (A) The mean diameter 
of the nanoprobe was plotted according to its concentration (0.5-5 mg/ml). (B)  
Monitoring particle size according to incubation time. CSOAA-based nanoprobe (at 
5 mg/ml concentration) was dissolved in PBS (pH 7.4) or 50% (v/v) FBS solution 
(in PBS pH 7.4). Data are expressed as mean ± SD (n = 3).
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Figure 6 TEM image (A) and size distribution (B) of CSOAA-DTPA-Gd 











Figure 7 CAC determination of the CSOAA-based nanoprobe. The fluorescence 
intensity ratio (I373/I383, I1/I3) was plotted according to nanoprobe concentration and 




























Figure 8 In vitro cytotoxicity tests of the CSOAA-based nanoprobe in (A) Hep-2 
and (B) FaDu cells after 12 and 24 h of incubation. Cell viability (%) was measured 
by MTS-based assay according to nanoprobe concentration. Data are expressed as 













Figure 9 Cellular uptake studies of the nanoprobe in Hep-2 and FaDu cells. 
Intracellular uptake and distribution of the Cy5.5-labeled nanoprobe were visualized 
by CLSM. Merged images of the control (no treatment), and 0.5 h, 8 h and 12 h 
incubation groups are shown. Red and blue indicate Cy5.5 and DAPI, respectively. 















Figure 10 In vitro MRI test of Magnevist (Gd-DTPA) and CSOAA-DTPA-Gd at 
4.7-T. (A) T1-weighted phantom image with 5–100 µM Gd concentrations was 






PART III. Polyethylene glycol-modified arachidyl 
chitosan-based nanoparticles for prolonged blood 





Nano-sized carriers have been developed for anti-cancer drug delivery to 
tumor regions to overcome the intrinsic drawbacks of using the pure drug, which 
include a short half-life and undesired distribution to normal tissues and organs (Bae 
et al., 2007; Cho et al., 2011; ElBayoumi and Torchilin, 2009; Jin et al., 2012; Mu 
et al., 2010; Xiao et al., 2012; Yang et al., 2007). Several approaches for modifying 
the surfaces of nanovehicles to modulate the pharmacokinetic and pharmacodynamic 
properties of drugs have been investigated. Shielding groups, adsorbed or conjugated 
to the surface of nanoparticles, can disturb the electrostatic and hydrophobic 
interactions between opsonins and nanoparticles (Owens and Peppas, 2006). Among 
them, PEG has been grafted or adsorbed onto the drug itself or polymers (Cho et al., 
2012b; Kaminskas et al., 2013; Veronese et al., 2005). It is known that an outer PEG 
shell can prevent the opsonization of nanoparticles in the blood and maintain their 
camouflage for phagocytosis (Owens and Peppas, 2006). Thus, this “stealth effect” 
can enhance systemic drug exposure and prolong circulation of nanocarriers in the 
blood stream. It has also been reported that the density of the PEG chain on the 
surface of nanoparticles may affect their interaction with blood components and 
macrophages (Owens and Peppas, 2006). Studies of the influence of PEG 
conjugation to various polymeric nanoparticles, for anti-cancer drug delivery, on the 
blood circulation time and anti-tumor efficacy have been reported (Cho et al., 2012b; 
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Lv et al., 2012; Qu et al., 2009; Yadav et al., 2011). Moreover, a PEG shell on 
nanoparticles containing anti-cancer agents reduced their hematological toxicity 
after intravenous administration (Jain et al., 2012); thus, it can be used to mask the 
toxicity of polymeric matrix in the blood stream.  
Natural polymers and their derivatives have been widely used for the 
development of self-assembled nanoparticles for cancer therapy and diagnosis (Cho 
et al., 2012a; Chung et al., 2013; Lee et al., 2011; Nogueira et al., 2013). In our 
previous reports (Termsarasab et al., 2013a,b), chitosan oligosaccharide-arachidic 
acid (CSOAA), as an amphiphilic chitosan oligosaccharide derivative, was 
synthesized, and self-assembled nanoparticles based on CSOAA were prepared. 
CSOAA-based nanoparticles were developed for delivery of anti-cancer drugs to the 
tumor region and cancer diagnosis. Although anti-tumor efficacy after intravenous 
injection based on passive targeting strategy, mainly due to the enhanced 
permeability and retention (EPR) effect, has been achieved in a head and neck cancer 
xenograft mouse model, the nanoparticles developed may exhibit greater in vivo 
anti-tumor efficacy as a result of the surface modification. Here, PEGylated 
CSOAA-based nanoparticles were prepared in an effort to prolong their circulation 
in the blood stream after intravenous administration. CSOAA-PEG conjugate was 
synthesized, and the physicochemical properties of CSOAA-PEG nanoparticles 
were investigated. Their application for leukemia therapy was tried and the 








Chitosan oligosaccharide (CSO; average molecular weight = 5 kDa, 
deacetylation degree > 90%) was obtained from Kitto Life Co., Ltd. (Seoul, Korea). 
Arachidic acid (AA), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), N-
hydroxysuccinimide (NHS), deuterochloroform (CDCl3) and deuterium oxide (D2O) 
were purchased from Sigma–Aldrich Co. (St. Louis, MO, USA). 
Methoxypolyethylene glycol succinimidyl succinate (mPEG-SS; molecular weight 
= 2 kDa) was provided by Sunbio Co. (Anyang, Korea). Doxorubicin hydrochloride 
(DOX HCl) was purchased from Boryung Pharmaceutical Co., Ltd. (Seoul, Korea). 
RPMI 1640 medium, penicillin, streptomycin, and heat-inactivated fetal bovine 
serum (FBS) were purchased from Gibco Life Technologies Inc. (Grand Island, NY, 
USA). All other reagents were of analytical grade and were obtained from 
commercial sources. 
 
2.2. Synthesis and characterization of CSOAA-PEG 
 
CSOAA was synthesized as described in our previous report, with slight 
modifications (Termsarasab et al., 2013a). Briefly, CSO (0.2 mmol) and AA (1 mmol) 
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were solubilized in 25 ml dimethyl sulfoxide (DMSO) separately at 50 °C for 15 min 
and cooled to room temperature. EDC (1.5 mmol) and NHS (1.5 mmol) were added 
to the AA solution and stirred for 30 min. Then, the AA solution was added to the 
CSO solution; the reaction was conducted for 12 h with stirring. That solution was 
then adjusted to pH 3.5 with 1 N HCl, prior to precipitating with 450 ml acetone 
three times to remove unreacted AA. The precipitate was collected by centrifugation 
(8608×g, 30 min), and resuspended in 50-ml double-distilled water (DDW). This 
solution was dialyzed (dialysis membrane molecular weight cut-off = 1 kDa; 
Spectrum Laboratories, Laguna Hills, CA, USA) against DDW for 2 days. CSOAA 
was obtained after freeze-drying. 
To synthesize CSOAA-PEG, CSOAA (0.125 mmol) was solubilized in 30-ml 
DMSO, followed by addition of mPEG-SS (0.25 mmol). After stirring for 12 h, the 
solution was dialyzed (dialysis membrane molecular weight cut-off = 3.5 kDa) 
against DDW for 1 day and then freeze-dried. The freeze-dried product was 
precipitated by adding excess acetone to remove unreacted mPEG-SS. The 
precipitate was collected by filtering and dried at 60 °C. The conjugations of CSOAA 
and CSOAA-PEG were confirmed by 1H-NMR analysis (Varian FT 500-MHz, 
Varian Inc., Palo Alto, CA, USA). To prepare the 1H-NMR samples (15 mg/ml 
concentration), CSOAA and CSOAA-PEG were dissolved in D2O and mPEG-SS 
was solubilized in CDCl3, respectively. Standard samples were prepared by mixing 
mPEG-SS and CSOAA at various molar ratios (0.5:1, 1:1, 1:2, 1:3, and 1:4) and 
freeze-drying for the determination of molar substitution (MS) of CSOAA-PEG. The 
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MS of CSOAA-PEG was calculated based on the ratio of the integration values of 
the CSOAA and mPEG-SS 1H NMR spectra. Those substances were dissolved in 
DMSO-d6. 
 
2.3. Preparation and characterization of DOX-loaded 
nanoparticles 
 
DOX-loaded CSOAA and CSOAA-PEG nanoparticles were prepared by a 
solvent evaporation method as reported previously (Termsarasab et al., 2013a). DOX 
base was prepared by the reaction between DOX HCl and triethylamine in DMSO 
for 12 h and lyophilization. CSOAA or CSOAA-PEG and DOX base (7.5:1.5, w/w) 
were dissolved in DMSO and DDW mixture (1:1, v/v). The solvent was removed 
under a nitrogen gas stream at 70 °C for 4 h. The drug and polymer film coated-tube 
was hydrated with DDW, followed by sonication using a probe sonicator (Vibra-
Cell, Sonics & Materials Inc., CT, USA) for 5 min. The nanoparticle suspension was 
then filtered through a syringe filter with 0.45-µm pore size (Minisart RC15; Satorius 
Stedim Biotech GmbH, Gottingen, Germany) to remove unloaded DOX. The 
average mean diameter, polydispersity index, and zeta potential values of DOX-
loaded CSOAA and CSOAA-PEG nanoparticles in DDW were measured using a 
dynamic light scattering (DLS) spectrophotometer (ELS-Z; Otsuka Electronics Co. 
Ltd., Osaka, Japan). Change of particle size (nm) in DDW and 50% (v/v) FBS was 
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also measured according to the incubation time (0.5, 1, 1.5, 2, 4, 6, 24, 48, and 72 h). 
The morphology of nanoparticles was observed by transmission electron microscopy 
(TEM; LIBRA 120; Carl Zeiss, Oberkochen, Germany). Samples were stained with 
2% (w/v) phosphotungstic acid, loaded on a copper grid coated with carbon film, 
and dried at 20 °C. To determine the encapsulation efficiency (EE) of the drug, 
aliquots of samples (0.1 ml of each nanoparticle suspension) were diluted with a 
100×volume of DMSO to disrupt the nanoparticles. DOX content was analyzed by 
a high-performance liquid chromatography (HPLC) method using a Waters HPLC 
system (Waters Co., Milford, MA, USA) equipped with a reversed-phase (RP) C-18 
column (Xbridge, RP-18, 250 mm×4.6 mm, 5 µm; Waters Co.), a separation module 
(Waters e2695), and a fluorescence detector (Waters 2475). The mobile phase 
consisted of 10 mM K2HPO4 (pH 2.5) and 0.01% (v/v) triethylamine in acetonitrile 
(71:29, v/v) with a flow rate of 1 ml/min. The excitation and emission wavelengths 
were 470 and 565 nm, respectively. The injection volume was 20 µl. The inter-day 
and intra-day variances were within the acceptable range. The EE value of DOX in 
nanoparticles was determined by the following equation: 
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2.4. In vitro DOX release test 
 
DOX-loaded CSOAA or CSOAA-PEG nanoparticles (150 µl) were loaded 
in a mini GeBA-flex tube (molecular weight cut-off: 12–14 kDa, Gene Bio-
Application Ltd., Kfar Hanagide, Israel) and placed in 15 ml of phosphate-buffered 
saline (PBS: pH 5.5, 6.8, and 7.4, adjusted with phosphoric acid). The drug release 
test was conducted in a shaking bath at 37 °C and 50 rpm rotation speed. Aliquots of 
release medium (200 µl) were collected at set times (1, 2, 3, 4, 6, 9, 12, 24, 48, 72, 
96, and 120 h), and an equivalent volume of fresh medium was replaced. The amount 
(%) of DOX released was determined by the HPLC method described above. 2.5. In 
vitro cytotoxicity of CSOAA and CSOAA-PEG Human leukemia K562 cells were 
purchased from the Korean Cell Line Bank (Seoul, Korea). The cells were cultured 
in RPMI 1640 medium containing 10% FBS, 100 U/ml penicillin, and 100 µg/ml 
streptomycin at 37 °C in a 5% CO2 atmosphere and 95% relative humidity. The 
cytotoxicities of CSOAA and CSOAA-PEG to K562 cells were determined using a 
3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H 
tetrazolium (MTS)-based assay. Various concentrations (∼100 µg/ml) of CSOAA 
and CSOAA-PEG were added to 1×104 cells suspended in 100 µl culture media and 
incubated for 24, 48, and 72 h. Then, the cells were treated with the MTS-based 
CellTiter 96 AQueous One Solution Cell Proliferation Assay Reagent (Promega Corp., 
Madison, WI, USA) at 37 °C for 4 h, according to the manufacturer’s protocol. The 
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absorbance at 490 nm was measured using a microplate reader (EMax, Molecular 
Devices, Sunnyvale, CA). 
 
2.5. In vitro cytotoxicity of CSOAA and CSOAA-PEG 
 
Human leukemia K562 cells were purchased from the Korean Cell Line Bank 
(Seoul, Korea). The cells were cultured in RPMI 1640 medium containing 10% FBS, 
100 U/ml penicillin, and 100 µg/ml streptomycin at 37 °C in a 5% CO2 atmosphere 
and 95% relative humidity. The cytotoxicities of CSOAA and CSOAA-PEG to K562 
cells were determined using a 3-(4,5-dimethylthiazol-2-yl)-5(3-
carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)-based assay. 
Various concentrations (∼100 µg/ml) of CSOAA and CSOAA-PEG were added to 
1 × 104 cells suspended in 100-µl culture media and incubated for 24, 48, and 72 h. 
Then, the cells were treated with the MTS-based CellTiter 96 AQueous One Solution 
Cell Proliferation Assay Reagent (Promega Corp., Madison, WI, USA) at 37 °C for 
4 h, according to the manufacturer’s protocol. The absorbance at 490 nm was 







2.6. In vitro cellular uptake study 
 
K562 cells at a density of 6×105 per well were treated with free DOX, DOX-
loaded CSOAA nanoparticles, or CSOAA-PEG nanoparticles at an equivalent DOX 
concentration (15 µg/ml). After the cells were incubated for 1 h, they were washed 
with PBS (pH 7.4) and resuspended in medium with 2% (v/v) FBS. DOX uptake 
efficiency was evaluated by flow cytometry using a FACSCalibur equipped with the 
CELLQuest software (Becton Dickinson Biosciences, San Jose, CA, USA). 
 
2.7. In vivo pharmacokinetics in rats 
 
Animal study protocol was approved by the Institutional Animal Care and Use 
Committee of Seoul National University (Seoul, Korea). Male Sprague-Dawley (SD) 
rats, weighing 250 – 300 g (Orient Bio, Inc., Seongnam, Korea), were used. The rats 
were housed under standard room (Animal Center for Pharmaceutical Research, 
College of Pharmacy, Seoul National University) at a temperature of 20 – 23 °C and 
a relative humidity of 50 ± 5%. A polyethylene tube (PE-50; Clay Adams, 
Parsippany, NJ, USA) was cannulated into the femoral veins and arteries of rats 
under ketamine anesthesia (50 mg/kg, intramuscular injection). Each group was 
administered at a single dose of 4 mg/kg DOX intravenously via the femoral vein. 
Blood samples (300 µl) were then collected via the femoral artery at 0, 2, 5, 15, 30, 
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60, 90, 120, 180, 240, 360, and 480 min and centrifuged (16,000×g, 5 min). Aliquots 
(150 µl) of plasma were stored at −20 °C until the quantitative analysis of DOX. The 
DOX concentration in plasma was analyzed by a reported HPLC method (Cho et al., 
2012b) with slight modifications. An aliquot of plasma sample (150 µl) with 
propranolol solution (internal standard, 50 µl, 1 µg/ml) was mixed with acetonitrile 
(400 µl). After vortexing and centrifuging (16,000×g, 10 min), supernatant (300 µl) 
was transferred to a clean tube and evaporated under a gentle stream of nitrogen at 
40 °C. The residue was reconstituted with 60-µl mobile phase (a mixture of 10 mM 
K2HPO4 (pH 2.5) and 0.01% (v/v) triethylamine in acetonitrile, 73:27, v/v). After 
vortexing and centrifuging, a 10-µl aliquot was subjected to HPLC analysis. The 
samples were injected into the RP-HPLC column as described above. The 
fluorescence intensity was monitored at excitation/emission wavelengths of 470/565 
nm for DOX, and 230/540 nm for propranolol. The lower limit of quantification 
(LLOQ) value of DOX in rat plasma was 0.01 µg/ml. The intra-day and inter-day 
coefficients of variation were within the acceptable range. The total area under the 
plasma concentration–time curve from time zero to infinity (AUC), terminal half-
life (t1/2), time-averaged total body clearance (CL), apparent volume of distribution 
at steady state (Vss), and mean residence time (MRT) were calculated using the 






2.8. Statistical analysis 
 
Statistical analysis was conducted using t-test and analysis of variance 
(ANOVA). All experiments were performed at least three times. The data are shown 
as means ± standard deviation (SD). 
 
3. Results and discussion 
 
3.1. Synthesis of CSOAA-PEG 
 
PEGylated CSOAA was synthesized to develop nanoparticles for DOX delivery. 
The synthetic method for CSOAA was reported in our previous study (Termsarasab 
et al., 2013a). Briefly, CSOAA was synthesized by a coupling reaction between the 
amine groups of CSO and carboxyl groups of AA using EDC and NHS as coupling 
reagents. EDC was introduced into the carboxyl groups of AA, and an AA-NHS 
intermediate was formed by adding NHS to EDC active ester. This intermediate was 
reacted with the amine group of CSO to generate CSOAA. Then, mPEG-SS was 
introduced to the remaining amine groups of CSOAA. To characterize the structure 
of CSOAA and CSOAA-PEG, 1H NMR analyses of mPEG-SS, CSOAA, and 
CSOAAPEG were performed; their spectra are shown in Fig. 1. The proton peaks of 
the alkyl chain and methyl group of AA appeared at 1.2 and 0.8 ppm, respectively. 
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The specific proton peaks for the oxyethylene group (-CH2CH2O-) and methoxy 
group (CH3O-) of mPEG appeared at 3.5–3.7 ppm and 3.3 ppm, respectively. The 
proton peaks between 2.5 and 3.0 ppm were corresponded to the succinimidyl 
succinate group of mPEG-SS. Compared with CSOAA and mPEG-SS, the 1H NMR 
spectrum of CSOAA-PEG exhibited the specific proton peaks of CSOAA and mPEG, 
while the proton peak of the succinimidyl succinate group shifted to 2.2 ppm. These 
results confirmed PEG conjugation to CSOAA. A homogeneous physical mixture of 
CSOAA and PEG was prepared and each component was analyzed by 1H NMR to 
calculate the molar substitution (MS) of PEG to CSOAA, according to a modified 
method reported previously (Termsarasab et al., 2013a). The molar substitution of 
PEG to CSOAA was calculated using the linear regression line, which was plotted 
between the integration ratio of the methoxy group of PEG (δ = 3.3; CH3O-) to the 
N-acetyl proton group of CSO (δ = 1.8; CH3CONH-), and the molar ratio of mPEG-
SS to CSOAA prepared from standard samples (Fig. 2). The molar substitution (mole 
of mPEG-SS/mole of CSOAA) of PEG to CSOAA was 1.8 in this investigation. 
 
3.2. Preparation and characterization of DOX-loaded 
nanoparticles 
 
Based on the CSOAA-PEG synthesized, nanoparticles loaded with DOX were 
prepared using a solvent evaporation method (Termsarasab et al., 2013a). In this 
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study, CSOAA/DOX and CSOAAPEG/DOX, at a weight ratio of 7.5–1.5 (polymer 
to drug), nanoparticles were prepared (Fig. 3). The mean diameters of the 
CSOAA/DOX and CSOAA-PEG/DOX nanoparticles were 124.17 ± 2.58 and 
165.75 ± 6.75 nm, respectively (Table 1). As shown in Fig. 4b, TEM image of the 
CSOAA-PEG/DOX nanoparticles showed a spherical shape and similar particle size 
to that measured by ELS. The hydrophilic PEG, conjugated to CSOAA, constituted 
the outer shell of the nanoparticles (Fig. 3). Because of this PEG shell, the mean 
diameter of drug-loaded CSOAA/PEG nanoparticles was increased versus drug-
loaded CSOAA nanoparticles. This phenomenon was also reported by us previously 
(Cho et al., 2012b) for amphiphilic hyaluronic acid oligomer-based nanoparticles. 
Despite the outer hydrophilic PEG shell on the CSOAA-based nanoparticles, the 
mean diameter was less than 200 nm, indicating a low probability of 
reticuloendothelial system (RES) clearance (Gaucher et al., 2005). The 
polydispersity index of PEGylated CSOAA-based nanoparticles containing DOX 
was 0.19 ± 0.03, indicating a narrow size distribution (Fig. 4a). The zeta potential 
value of the CSOAA-PEG/DOX nanoparticles was lower than that of the 
CSOAA/DOX nanoparticles (p < 0.05), possibly due to the presence of the outer 
PEG shell. 
The mean diameters of drug-loaded CSOAA and CSOAA-PEG nanoparticles 
were measured in DDW and those values of both nanoparticle groups were 
constantly maintained for 72 h (Fig. 5a). However, they are not enough to reflect the 
actual particle size in the blood stream. Additionally, in vivo pharmacokinetic and 
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pharmacodynamics performances cannot be predicted precisely from particle size 
measurements in DDW. Nanoparticles administered by the intravenous route can 
interact with blood components and form large aggregates or complexes (Liu et al., 
2012; Rausch et al., 2010). These unwanted aggregates can inhibit normal blood 
circulation and are readily eliminated by RES organs (liver and spleen). Thus, 
changes in particle size in the presence of serum (50%, v/v) were monitored 
according to the incubation time. As shown in Fig. 5b, the mean diameter of 
CSOAA-PEG/DOX nanoparticles increased by 20.92% over 72 h, while 
CSOAA/DOX nanoparticles showed a 223.16% increase in mean diameter during 
the same period. The hydrophilic PEG shell of CSOAA-PEG/DOX nanoparticles 
hampered the interaction between blood constituents and the chitosan-based surface, 
and thus reduced the aggregation of nanoparticles in the presence of serum. 
Maintaining the initial mean diameter of PEGylated nanoparticles under serum 
conditions can lead to the improved stability by “stealth effect” (Qu et al., 2009; 
Zhang et al., 2013), and thereby prolonging circulation of the nanoparticles in the 
blood stream. 
 
3.3. In vitro drug release 
 
DOX release in vitro from the nanoparticle formulations was monitored at pH 
5.5, 6.8, and 7.4 (Fig. 6). DOX release profiles from CSOAA-based nanoparticles 
under several pH conditions have been reported previously (Termsarasab et al., 
86 
 
2013a). Despite different weight ratios between CSOAA and DOX compared with 
the current study, DOX release was improved in acidic pH condition. In this 
investigation, the proportions (%) of DOX released from CSOAA and CSOAA-PEG 
nanoparticles after 24 h were 56.69 ± 4.04% and 31.19 ± 0.95%, respectively. After 
a steady increase in DOX release from the CSOAA-PEG nanoparticles, the two 
values reached 56.02 ± 2.07% and 50.77 ± 5.88%, respectively, at day 5. Although 
the proportions of DOX released from both nanoparticle formulations were similar 
at steady state (around day 5), a sustained pattern of DOX release from the CSOAA-
PEG nanoparticles was observed. Thus the PEG shell may delay drug diffusion and 
dissolution from the reservoir. Sustained drug release from PEGylated nanoparticle 
formulations has been reported previously (Cho et al., 2012b; Jain et al., 2012). 
Additionally, pH-dependent DOX release from CSOAA-PEG nanoparticles was 
observed. The proportions of DOX released from CSOAA-PEG nanoparticles at pH 
7.4 and 5.5 on day 5 were 50.77 ± 5.88% and 83.57 ± 0.24%, respectively. This can 
be explained by the higher solubility of DOX under acidic pH conditions and 
changes in the binding strength between the drug and nanoparticle structure (Jin et 
al., 2012; Nukolova et al., 2011; Termsarasab et al., 2013a). Enhanced DOX release 
at pH 5.5 and 6.8, which reflects the conditions in endocytic compartments 
(endosomes and lysosomes, pH 5.5) and the tumor microenvironment (pH 6.8), may 





3.4. In vitro cytotoxicity 
 
The cytotoxicity of CSOAA and CSOAA-PEG was assessed against K562 cells, 
human erythromyeloblastoid leukemia cells (Laroche-Clary et al., 2000), using an 
MTS-based assay. Cell viability (%) is presented after 24, 48, and 72 h of incubation 
with various concentrations of both conjugates (Fig. 7). One of the indications for 
DOX is leukemia; thus, K562 cells were used for determination of the cytotoxicity 
of the conjugates synthesized. Neither CSOAA nor CSOAA-PEG induced serious 
toxic effects in K562 cells at the concentrations tested after incubation for 24–72 h. 
In our previous study (Termsarasab et al., 2013a), CSOAA also showed no 
significant cytotoxicity in head and neck cancer cell line (FaDu cell). Our results 
here suggest that CSOAA-PEG can be used safely for the preparation of drug 
delivery vehicle. 
 
3.5. In vitro cellular uptake 
 
The cellular uptake efficiency of DOX from the nanoparticles developed was 
assessed using flow cytometry. In this investigation, the K562 cell was selected as a 
model cell line of human leukemia. DOX has been used in leukemia therapy in the 
clinic; thus, its uptake into K562 cells could be related to its anti-tumor efficacy. As 
shown in Fig. 8, DOX uptake was higher in the nanoparticle-treated groups than the 
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DOX solution-treated group. This might be due to the electrostatic interaction 
between the positive charge of the chitosan molecules and the negative charge of the 
cell membrane (Chavanpatil et al., 2006; Termsarasab et al., 2013a; Zauner et al., 
1998). As reported in other cell line (Termsarasab et al., 2013a), DOX uptake from 
CSOAA-based nanoparticle was enhanced compared with DOX solution in K562 
cells. However, the cellular uptake of DOX from the PEGylated CSOAA-based 
nanoparticles was lower than from CSOAA-based nanoparticles. This may be 
explained by the outer PEG shell reducing the electrostatic force between chitosan 
and the cell membrane, blocking interactions between the fatty acids in the minor 
hydrophobic core of the nanoparticles and the cell membrane, thus delaying drug 
release. Notwithstanding the lower cellular uptake efficiency of PEGylated CSOAA 
nanoparticles, they may exert a stealth effect, due to the prolonged circulation time 
in the blood stream after intravenous injection. 
 
3.6. In vivo pharmacokinetics in rats 
 
DOX-loaded nanoparticles were administered intravenously at a dose of 4 
mg/kg to rats to investigate their effects on the pharmacokinetic properties of DOX. 
The DOX concentration in plasma according to time is shown in Fig. 9, and the 
pharmacokinetic parameters are listed in Table 2. The pharmacokinetic parameters 
of a DOX solution (4 mg/kg dose)-treated group reported in our previous study (Cho 
et al., 2012b) were used as the control. CL values of CSOAA and CSOAA-PEG 
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nanoparticle groups were decreased, to 11.17% and 2.09% of the value of DOX 
solution. AUC values of CSOAA and CSOAA-PEG nanoparticle groups exhibited 
8.64- and 48.00-fold increases compared with that of the DOX solution group, 
respectively. Half-life (t1/2) values in both groups were increased to 173.50% and 
899.82%, respectively, compared with that of the DOX solution group. Additionally, 
MRT values showed 10.52- and 47.58-fold increases compared to the DOX solution 
group. These data indicated that the nanoparticles developed here exhibited lower in 
vivo clearance of DOX and prolonged circulation of nanoparticles in the blood 
stream. The PEGylated nanoparticles also showed decreased in vivo clearance, and 
increased AUC, half-life, and MRT values, compared with CSOAA-based 
nanoparticles (p < 0.05). It has been reported that nanoparticles modified with PEG 
exhibited enhanced systemic exposure of the drug after intravenous injection (Qu et 
al., 2009; Zhang et al., 2013). The decreased in vivo clearance of DOX in the 
PEGylated CSOAA nanoparticles seems to be based on their greater stability in the 
presence of serum (Fig. 5) and sustained drug release (Fig. 6). The stealth effect of 
the PEG shell likely contributes to the longer dosing interval and improved anti-
tumor efficacy. In particular, prolonged circulation of the CSOAA-PEG 
nanoparticles developed may be appropriate for the therapy of hematological 








PEGylated CSOAA-based nanoparticles containing DOX were developed to 
achieve a prolonged circulation time of the drug in the blood stream. Synthesis of 
the CSOAA-PEG conjugate was confirmed by 1H NMR analysis. DOX-loaded 
CSOAA-PEG nanoparticles with a ∼166-nm mean diameter and positive zeta 
potential were prepared and a sustained pattern of drug release from the CSOAA-
PEG nanoparticles was observed. The cytotoxicity of CSOAA-PEG in K562 cells 
seemed negligible in the concentration range tested, and the cellular uptake 
efficiency of the drug from nanoparticles was improved compared with DOX in 
solution. Decreased in vivo clearance and a longer DOX half-life in the blood stream 
in the CSOAA-PEG nanoparticles group was demonstrated in a pharmacokinetic 
study. The CSOAA-PEG nanoparticle developed may be a useful candidate of anti-
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Table 2. Pharmacokinetic parameters of DOX in rats after intravenous 
administration at a dose of 4 mg/kg. 
Parameter DOX solutiona CSOAA/DOX 
CSOAA-
PEG/DOX 
AUC (μg∙min/ml) 65.18 ± 16.47 563.24 ± 33.34# 3128.65 ± 621.52#,* 
Terminal t1/2 (min) 76.37 ± 8.83 132.50 ± 32.80# 687.19 ± 221.97#,* 
CL (ml/min/kg) 63.76 ± 14.18 7.12 ± 0.41# 1.33 ± 0.31#,* 
Vss (ml/kg) 1189.49 ± 204.99 1195.81 ± 192.67 1117.43 ± 207.24 
MRT (min) 18.82 ± 1.14 197.94 ± 64.87# 895.41 ± 319.77#,* 
 
# p < 0.05 compared to DOX solution group. 
*p < 0.05 compared to CSOAA/DOX nanoparticle group. 
Data present as mean ± SD (n ≥ 3). 





















Figure 1   1H-NMR spectra of CSOAA, mPEG-SS, and CSOAA-PEG. 














Figure 2 The correlationship between the ratio of integration area (3.33/1.98 ppm) 
and molar ratio of mPEG-SS/CSOAA based on their physical mixture. Each point 






























Figure 4 Characterization and illustration of CSOAA-PEG/DOX nanoparticles. (a) 


















Figure 5 The change in mean diameter (nm) of the nanoparticles in the presence of 
50% serum according to incubation time. CSOAA/DOX and CSOAA-PEG/DOX 
nanoparticles were incubated at 37°C for various periods. Each point represents the 











Figure 6 In vitro DOX release profiles of CSOAA and CSOAA-PEG-based 
nanoparticles. Drug release profiles of DOX-loaded CSOAA nanoparticles (pH 7.4) 
and CSOAA-PEG nanoparticles at pH 5.5, 6.8, and 7.4 are shown. Each point 



















Figure 7 In vitro cytotoxicity test of CSOAA (a) and CSOAA-PEG (b) in K562 cells. 
Each conjugate at various concentrations was incubated for 24, 48, and 72 h in the 









Figure 8 Flow cytometry analysis of DOX uptake by K562 cells. DOX solution (red), 
DOX-loaded CSOAA nanoparticles (blue), and DOX-loaded CSOAA-PEG 












Figure 9 In vivo pharmacokinetic profiles of DOX in rats. Nanoparticles were 
administered intravenously at a dose of 4 mg/kg. Each point represents the mean ± 




본 연구에서는 항암제인 독소루비신의 표적화 전달을 위해 키토산 올리고당 
유도체를 합성하여 자가조립 나노입자를 제조하였다. 양친매성을 가진 고분
자인 키토산-아라키드산(CSOAA)을 우선적으로 합성하였다. 이 고분자를 기
본골격으로 하여 약물의 혈중 순환을 연장시키기 위해 폴리에틸렌글리콜
(PEG)을 결합시켰고, 한편으로 암조직에 대한 자기공명영상 조영제로서의 
기능을 부여하기 위해 DTPA-Gd를 결합시켰다. CSOAA로 입자 제조시 
200nm 이하의 균일한 입도분포를 가진 나노입자가 형성되었고, 고분자의 
낮은 임계 미셀 농도를 통해 입자로서의 안정성을 가지는 것을 확인하였다. 
용출실험 결과 CSOAA 나노입자에서 약물의 서방출이 나타났고, 산성 조건
일수록 방출 속도가 더 증가하였다. FaDu 세포를 이용한 in vitro 세포 유입 
실험에서는 용액 상태보다 나노입자 형태로 적용할 때 세포내 약물 유입이 
증가하였다. FaDu 세포를 이식한 누드마우스를 이용한 In vivo 항암 실험에
서도 나노입자를 이용했을 때 더 우수한 항암효과가 나타났다. CSOAA-
DTPA-Gd 관련 실험에서, FaDu 세포와 Hep2 세포에 Cy5.5를 결합시킨 나노
탐침을 반응시킨 후 공초점레이저주사현미경으로 관찰한 결과 시간에 따라 
세포내 유입이 증가하는 것으로 나타났다. 이 함성 고분자를 이용한 팬텀 실
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험에서도 상용조영제인 마그네비스트보다 조영 효과가 높은 것으로 확인됐
다. CSOAA-PEG 관련 실험에서 혈청에서의 입자 안정성 시험을 진행한 결
과, 일반 CSOAA 입자의 경우 입자 크기가 크게 증가한 반면 CSOAA-PEG 입
자의 경우 72시간 이상 일정한 입자크기를 유지했다. 인간 백혈병 세포인 
K562 세포에 대한 약물 전달시험에서는 독소루비신 자체보다 나노입자에 
봉입된 상태로 적용된 경우 약물 유입이 높게 발생했다. in vivo 약물동태학 
실험에서 CSOAA-PEG 그룹의 경우 일반 CSOAA, 독소루비신 용액과 비교시 
약물의 소실 속도가 낮고 혈중 순환이 연장되는 것으로 나타났다. 위와 같은 
결과를 통해 키토산 유도체를 이용한 자가조립 나노입자는 표적화 치료 및 
암진단에 이용될 수 있음을 보여준다. 또한 이 시스템을 다른 약물에 응용하
여 암조직으로의 선택적 약물 전달을 향상시키고, 약물동태학적 특성, 항암
활성, 부작용 등을 최적화하는데 이용할 수 있을 것이다.  
 
주요어: 키토산-아라키드산, 가돌리늄, 폴리에틸렌글리콜, 독소루비신, 
나노입자, 항암효능 















Nanoparticles for cancer therapy
• Particles, usually comprising lipid or polymer




- Reducing P-gp efflux pump
Active targeting
- Specific receptor site on cell 
surface of tumor cell
Backgrounds
Kamaly et al., 2012 2
2
Polymer-based Nanoparticles
• The self-assembly of amphiphilic block of copolymer 
in aqueous environment
• Spherical, core/shell structure consist of hydrophobic 
core and hydrophilic shell
3
Schluep, T. et al., 2006.






• Soluble in water and various organic solvents
• Cationic polymer and low viscosity
• Biocompatibility, biodegradability and low toxicity
• Hydrophilic polymer contains with free amino 
groups
(Kumar et al., 2004)
Arachidic acid (AA)
• Saturated fatty acid with a 20-carbon chain
• Using as cell or skin permeation enhancer 
(Mittal et al., 2009)
Backgrounds
Polymer Hydrophobic part Drug References
chitosan 
oligosaccharide
stearic acid DNA Du et al., 2010
stearic acid/PEG mitomycin Hu et al., 2008
linoleic acid Doxorubicin Du et al., 2009






• MW of chitosan
• Substitution degree of fatty acid
3
5
Carbon number of fatty acid 
 particle size
 stability of nanoparticles
Lee et al., 2003
Polymer-based Nanoparticles (cont.)
Optimized chain length and 
hydrophobic interaction force
Rationale of CSOAA nanoparticles
6
• Novel type of fatty acid (arachidic acid) conjugated on chitosan
oligosaccharide
• Forming nanoparticle with nano-sized (<200 nm) and uniform size
distribution
• Low CAC value
Chitosan oligosaccharide
Arachidic acid
Challenging!!  The difficulty to synthesize CSOAA because of solubility  
problem of arachidic acid (very low solubility in organic solvents 















• Interacts with DNA by intercalation and inhibition of 
macromolecular biosynthesis (topoisomerase II inhibitor)
Indications
Combination therapy
• ABVD - doxorubicin, bleomycin, vinblastin, dacarbazine (Hodgkin's lymphoma)
• AC - doxorubicin, cyclophosphamide (breast cancer)
• CAV - cyclophosphamide, doxorubivin, vincristine (lung cancer)
• CHOP - cyclophosphamide, doxorubicin, vincristine, prednisone (non-Hodgkin lyphoma)
• TAC - docetaxel/paclitaxel, doxorubicin, cyclophosphamide (breast cancer)













CSOAA-based Nanoprobe PEGylated CSOAA
Part I. Chitosan oligosaccharide-
arachidic acid- based nanoparticles 
for anticancer drug delivery
Part II. Self-assembled magnetic 
resonance imaging nanoprobes
based on arachidyl chitosan for 
cancer diagnosis
Part III. Polyethylene glycol-modified 
chitosan-based nanoparticles for 
prolonged blood circulation of 
doxorubicin
5
• Chitosan oligosaccharide-arachidic acid- based 
nanoparticles for anticancer drug deliveryPart I
Objectives
To develop a novel self-assembled nanoparticle using chitosan oligosaccharide-
archidic acid (CSOAA) for anticancer drug delivery
- Improve cellular uptake and  anti-tumor efficacy of DOX
9
• CSO:AA:EDC:NHS = 1:3:4.5:4.5
• Controlled temperature about 30°C
• Decomposing CSO/AA physical complex pH titration at 3.5 
• Removing unreacted AA  Acetone (9:1) washing 3 times
• Removing unreacted EDC/NHS and by-product  Dialysis for 1 day
• lyophilization
Figure The synthesis schemes of CSO-AA by EDC coupling reaction








Synthesis of chitosan oligosaccharide-conjugated arachidic acid
In DMSO at 70°C
10
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Characterization of CSOAA nanoparticles
Figure. 1H-NMR spectrum of CSOAA.
Figure. Determination of the CAC of CSOAA.
Figure. The correlationship between the ratio of
integration are (1.23/1.81 ppm) and molar ration of
AA/CSO based on their physiochemical mixture.
AA
CSO
CAC = 1.42 µg/mL
Molar substitution ratio 
of AA on CSO = 1.00 
mole/mole
Low CAC form stable 
nanoparticulate structure 
after dilution with a large 
volume of body fluids.
Part I
11
Preparation and characterization of CSOAA nanoparticles
Solvent evaporation method
Figure. Size distribution and TEM images of DOX-
loaded CSOAA-based nanoparticles.
Figure. In vitro DOX release profiles from
CSOAA-based nanoparticles.
Figure. In vitro cytotoxicity test of CSOAA in
FaDu cells. Cell viability (%) was determined
by an MTS-based assays. Each point
represents the mean±SD (n = 3).
 narrow size distribution and spherical shape
 Sustained release profiles and high drug released rate and amount at 
acidic pH




In vitro cellular uptake study
In vivo antitumor efficacy
Figure. Cellular uptake efficiency of DOX in FaDu cells analyzed by flow
cytometry. DOX solution and DOX-loaded nanoparticles were incubated for 1 h.
CSOAA nanoparticles > DOX solution
*electrostatic interaction between chitosan and cell membrane
*hydrophobic core of nanoparticles may help the internalization of 
DOX into the cells
Cellular uptake efficiency
Figure. Anti-tumor efficacy test of DOX-loaded
CSOAA NPs in FaDu tumor-bearing BALB/c nude
mouse model. (a) Tumor volume (mm3) profiles
according to the time (days) for 18 days are shown.
DOX solution and DOX-loaded CSOAA NPs were
injected intravenously at a dose of 2.5 mg/kg on
day 6, 8, and 13. (b) Body weight (g) was monitored.
Each point indicates the mean±SD (n≥4). *P < 0.05
vs. control group; +P < 0.05 vs. DOX solution group.
CSOAA nanoparticles > DOX solution > control




• Self-assembled magnetic resonance imaging 




To develop arachidyl chitosan nanoprobe for magnetic resonance imaging (MRI) 
of cancer diagnosis
 Enhance the contrast efficiency of contrast agent
14
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Figure. Synthesis scheme of CSOAA-DTPA-Gd
Figure. FT-IR spectra of CSOAA-DTPA and CSOAA-DTPA-Gd
Synthesis and Characterization of CSOAA-DTPA-Gd
• EDC and NHS coupling reaction
• CSO:AA:EDC:NHS = 1:3:4.5:4.5
• CSOAA:DTPA:EDC:NHS = 1:5:10:10
• CSOAA-DTPA:Gd = 1:5
DTPA; diethylenetriamine pentaacetic dianhydride
GdCl3; gadolinium (III) chloride hexahydrate
Gd content in CSOAA-based nanoprobe = 5.43 % (w/w) 








Preparation and characterization of CSOAA-based nanoprobes
A B C D
Figure. Characteristics of the CSOAA-based nanoprobe.
Table. Characteristics of CSOAA, CSOAA-DTPA and CSOAA-DTPA-Gd nanoprobes (1 mg/mL).
Solvent evaporation method
The mean diameter of the nanoprobes
according to its concentration. 
TEM image of the
nanoprobes (2.5 mg/ml).
The size distribution of the
nanoprobes (2.5 mg/ml).









In vitro cytotoxicity tests
Figure. In vitro cytotoxicity tests of CSOAA-based nanoprobes in (A)
Hep-2 and (B) FaDu cells after 12 and 24 h of incubation. Cell
viability was measured by MTS-based assay according to
nanoparobe concentration. Data are express as means ± SD (n=4).
In vitro cellular uptake of
nanoprobes
Figure. Cellular uptake studies of the nanoprobe in Hep-2 and 
FaDu cells. Intracellular uptake and distribution of the Cy5.5-
labled nanoprobe were visualized by CLSM. Red and blue 
indicate Cy5.5 and DAPI, respectively.
No severe toxicity to Hep-2 and FaDu cells increasing cellular uptake according to
incubation time in Hep-2 and FaDu cells
Cy 5.5-labled CSOAA-based nanoprobes
Cy5.5 content of Cy5.5-CSOAA-DTPA-Gd = 0.13 %w/w










𝑑 + 𝑅1 𝑀
• R1 is relaxivity.
• (1/T1)obs and (1/T1)d are the relaxation rates of the protons in
the presence and absence of paramagnetic species (Gd),
respectively
• [M] is the concentration of the parameagnetic species (Gd).
In vitro MRI study (Phantom study)
Figure. In vitro MRI test of Magnevist (Gd-DTPA) and CSOAA-DTPA-
Gd at 4.7T. (A) T1-weighted phantom image with 5-100 µM Gd
concentrations was shown. (B) Longitudinal relaxation (1/T1)
according to the Gd cencentration was plotted.
Increasing of T1 relaxivity (R1)
CSOAA-base nanoprobe > Manevist®
(2.43 fold) 
T1 contrast intensity of Magnevist® and CSOAA-based
nanoparobe were scanned using a 4.7-T MRI apparatus.
*Several hydroxyl groups of CSOAA can attract 
adjacent water molecules





• Polyethylene glycol-modified chitosan-based 




To develop PEGylated arachidyl chitosan-based nanoparticles for prolong blood 
circulation of anticancer drugs
- Improve pharmacokinetics of DOX
19
Synthesis and characterization of CSOAA-PEG
Figure. 1H-NMR spectrum of CSOAA, m-PEG, and CSOAA-PEG.
Figure. Synthetic scheme of CSOAA-PEG.
Molar substitution ratio of 
CSOAA-PEG was 1.82 mole/mole.
Figure. Correlation between the ratio of integration area 
(I3.3/I1.81) and molar ratio of mPEG-SS/CSOAA






Preparation and characterization of DOX-loaded nanoparticles













124.17 ± 2.58 0.20 ± 0.04 27.28 ± 1.50 60.03 ± 2.14
CSOAA-PEG/DOX
(7.5 / 1.5)
165.75 ± 6.75 0.19 ± 0.03 21.47 ± 2.05 63.80 ± 3.19
Solvent evaporation method
Figure. Size distribution of DOX/CSOAA-PEG
nanoparticles.
Figure. TEM image of DOX/CSOAA-PEG
nanoparticles.








In vitro cytotoxicity test
Figure. In vitro DOX release profiles of CSOAA and CSOAA-PEG-based
nanoparticles. Drug release profiles of DOX-loaded CSOAA nanoparticles (pH
7.4) and CSOAA-PEG nanoparticles at pH 5.5, 6.8, and 7.4 are shown. Each
point represents the mean ± SD (n = 3).
 DOX released from CSOAA and CSOAA-PEG nanoparticles were 
similar at steady state at pH 7.4.
 CSOAA-PEG nanoparticles show sustained and high drug released 
rate and amount at acidic pH 
In vitro drug release
CSOAA CSOAA-PEG
Figure. In vitro cytotoxicity test of CSOAA (a) and CSOAA-PEG (b) in K562 cells. Each conjugate at various concentrations
was incubated for 24, 48, and 72 h in the presence of the cells. Each point represents the mean ± SD (n = 4).
CSOAA and CSOAA-PEG have not 
serious toxic effects at the tested 




In vitro cellular uptake
Figure. Flow cytometry analysis of intracellular
DOX intensity in K562 cells at 1 and 2 h after
exposing the cells to free DOX, DOX-loaded CSOAA
or DOX-loaded CSOAA-PEG (DOX concentration 15
µg/ml).
CSOAA > CSOAA-PEG > DOX solution
*PEG shell may
- reduce the electrostatic force between chitosan and cell 
membrane








*, p<0.05 compared to 1 h incubation time in each group.
#, p<0.05 compared to DOX solution group.




In vivo pharmacokinetics in rats
Parameter DOX solutiona CSOAA/DOX CSOAA-PEG/DOX
AUC (μg∙min/ml) 65.18 ± 16.47 563.24 ± 33.34# 3128.65 ± 621.52#,*
Terminal t1/2 (min) 76.37 ± 8.83 132.50 ± 32.80
# 687.19 ± 221.97#,*
CL (ml/min/kg) 63.76 ± 14.18 7.12 ± 0.41# 1.33 ± 0.31#,*
Figure. In vivo pharmacokinetic profiles of DOX in rats. Nanoparticles were
administered intravenously at a dose of 4 mg/kg. Each point represents the
mean ± SD (n ≥ 3).
# p < 0.05 compared to DOX solution group.
*p < 0.05 compared to CSOAA/DOX nanoparticle group.
Data present as mean ± SD (n ≥ 3).
aData were cited from our previous report (Cho et al., 2012b).
↑AUC, t1/2
↓CL
PEGylation could prolong circulation







 Small nanoparticles size (< 100 in blank nanoparticles) 
with low size distribution and CAC value
 Enhancing solubility of drugs
 Improving cellular uptake of drug into cancer cells
 Improving anticancer activity of anticancer drug
 Improving contrast efficiency of contrast agents
 Decreasing in vivo clearance of drug and prolonging 
blood circulation of time of nanoparticles (PEGylated
nanoparticles)
25
The CSOAA-based nanoparticles could be an effective candidate for targeted
delivery of anticancer drugs. They could be applied to improve the specific
uptake of anticancer drugs at tumor site, thereby optimizing pharmacokinetics
and antitumor efficacy. These drug delivery systems could be further developed
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Figure Nanoparticles can enter cells via
endocytosis. This figure shows a transmission
electron micrograph of nanoparticles at the
surface of a cancer cell, entering the cell and
within endocytic vesicles.
Davis et.al, 2008.
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a  b  s  t  r  a  c  t
Chitosan  oligosaccharide–arachidic  acid  (CSOAA)  conjugate  was  successfully  synthesized  and  used  for  the
development  of self-assembled  nanoparticles  for doxorubicin  (DOX)  delivery.  The molar  substitution  of
AA  on  CSO  and  critical  micelle  concentration  (CMC)  of  CSOAA  were  measured.  Physicochemical  properties
of DOX-loaded  CSOAA-based  nanoparticles,  such  as  particle  size,  zeta  potential  and  morphology,  were
also characterized.  The  DOX-loaded  CSOAA-based  nanoparticles  showed  spherical  shape  with  a  mean
diameter  of  130 nm  and  positive  charge.  According  to  the  result  of in  vitro  release  test,  DOX-loaded  CSOAA-rachidic acid
hitosan oligosaccharide
oxorubicin
ead and neck cancer
elf-assembly
based  nanoparticles  exhibited  sustained  and  pH-dependent  drug  release  profiles.  The  CSOAA  showed
negligible  cytotoxicity  in  FaDu,  human  head  and  neck  cancer,  cells.  Cellular  uptake  of DOX  in  FaDu  cells
was  higher  in the  nanoparticle-treated  group  compared  to  the  free  DOX  group.  The  anti-tumor  efficacy
of DOX-loaded  nanoparticles  was  also  verified  in  FaDu  tumor  xenografted  mouse  model.  These  results
suggested  that synthesized  amphiphilic  CSOAA  might  be  used  for the  preparation  of self-assembled
nanoparticles  for anti-cancer  drug  delivery.. Introduction
Polymeric nanoparticles have been widely investigated as drug
arriers for anti-cancer agents (Cho et al., 2011; Choi et al.,
012; Kaida et al., 2010; Kolishetti et al., 2010; Yoon et al.,
012). Self-assembly based on amphiphilic polymer has been
idely investigated because it has many interesting properties.
mphiphilic polymers can form stable nanoparticles composed of
 hydrophobic core and a hydrophilic shell in an aqueous envi-
onment. Poorly water-soluble drugs can be encapsulated in the
nternal hydrophobic cavity, which can improve their solubility
nd bioavailability (Aliabadi et al., 2005; Kwon, 2003; Li and Tan,
008). The nano-size and hydrophilic shell of these self-assembled
anoparticles can impede elimination by the reticuloendothelial
ystem (RES) and have an enhanced permeability and retention
EPR) effect as a passive targeting strategy, leading to effective
ccumulation of drugs at the tumor region (Maeda et al., 2000).Doxorubicin (DOX) is an anthracycline antibiotic that is
ommonly used in the treatment of various types of cancer,
uch as hematological malignancies, breast carcinomas, ovarian
∗ Corresponding authors. Tel.: +82 2 880 7870; fax: +82 2 873 9177.
E-mail addresses: htmoon@snu.ac.kr (H.T. Moon), ddkim@snu.ac.kr (D.-D. Kim).
1 These authors have equally contributed.
378-5173/$ – see front matter ©  2012 Elsevier B.V. All rights reserved.
ttp://dx.doi.org/10.1016/j.ijpharm.2012.11.018© 2012 Elsevier B.V. All rights reserved.
carcinomas, bronchogenic carcinomas, and soft-tissue sarcomas.
DOX has also exhibited therapeutic effects for head and neck
cancer (Airoldi et al., 2008), which includes several types of tumor
localized in the oral cavity, nose, throat, sinuses, and salivary glands
(Cho et al., 2012a). The response rate for anti-cancer therapeutics is
known to be relatively low in head and neck cancer, with a survival
benefit of about 10 weeks for patients with recurrent/metastatic
disease (Reuter et al., 2007). Although DOX shows high potential
anti-cancer efficacy, its clinical application is limited because of its
severe side effects, especially cardiotoxicity and myelosuppression
(Kratz et al., 2007; Wildiers et al., 2008). Therefore, it is thought
that tumor-targeting strategy can minimize these side effects (Cho
et al., 2012b).
Chitosan (CS) is a linear cationic polysaccharide composed of
randomly distributed -(1–4)-linked d-glucosamine and N-acetyl-
d-glucosamine units, produced by the deacetylation of chitin. CS
has been regarded as an attractive material for the development of
drug delivery systems due to its biocompatibility, biodegradabil-
ity, and low toxicity (Kumar et al., 2004; Muzzarelli and Muzzarelli,
2005). Moreover, CS has free primary amino groups, allowing for
further chemical modification. However, the major drawback of CS
is its poor solubility at physiological pH. Recently, many researchers
have investigated chitosan oligosaccharide (CSO), a low-molecular-
weight CS, because it can be soluble in water and several organic
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t al., 2004). CSO has been modified with hydrophobic residues,
uch as alkyl groups, cholesterol, tocopherol, and deoxycholic acid
Chae et al., 2005). These hydrophobically modified CSOs can form
elf-assembled nanoparticles, which can be used as carriers for
umor-targeted drug and gene delivery.
In this study, arachidic acid (AA), as a fatty acid, was  conjugated
o a CSO backbone to make an amphiphilic CSO derivative. DOX
as loaded into the self-assembled nanoparticles based on chi-
osan oligosaccharide–arachidic acid (CSOAA). The physiochemical
roperties of DOX-loaded CSOAA-based nanoparticles, such as par-
icle size, zeta potential and morphology, and in vitro drug release
ehavior were investigated. In vitro cytotoxicity and cellular uptake
fficiency were evaluated in head and neck cancer cells, and in vivo
nti-tumor efficacy was also assessed in the head and neck cancer
enografted mouse model.
. Materials and methods
.1. Materials
Chitosan oligosaccharide (CSO; average molecular weight =
 kDa, degree of acetylation > 90%) was purchased from
itto Life Co., Ltd. (Seoul, Korea). Arachidic acid (AA),
-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), N-
ydroxysuccinimide (NHS), and deuterium oxide were purchased
rom Sigma–Aldrich Co. (St. Louis, MO,  USA). Dimethylsulfoxide-d6
DMSO-d6) was purchased from Cambridge Isotope Laboratories
nc. (Andover, MA,  USA). Doxorubicin hydrochloride (DOX HCl)
as obtained from Boryung Pharmaceutical Co. (Seoul, Korea).
inimum essential medium (MEM), penicillin, streptomycin, and
etal bovine serum (FBS) were obtained from Gibco Life Tech-
ologies, Inc. (Grand Island, NY, USA). All other chemicals were of
eagent grade and were used without further purification.
.2. Synthesis and characterization of CSOAA
Amphiphilic CSOAA was synthesized from CSO and AA. Briefly,
SO (0.2 mmol) and AA (0.6 mmol) were dissolved separately in
0 ml  DMSO each at 50 ◦C for 15 min. Carboxyl groups of AA were
ctivated by adding EDC and NHS (1.5 mol/mol AA) and it was
tirred at room temperature for 30 min. Then, activated AA solution
as dripped into the CSO solution for 5 min. The coupling reaction
as conducted for a further 12 h, and then 4 ml  of deionized dis-
illed water (DDW) was added. The pH of the mixture was adjusted
o 3.5 with 1 N HCl and stirred for 30 min. The mixture was  pre-
ipitated by adding acetone (ten times the volume of mixture) and
entrifuged (8608 × g, 30 min) to remove unreacted AA. The precip-
tation step was repeated three times. Next, the precipitate was dis-
ersed with DDW and dialyzed with dialysis membrane (molecular
eight cut-off = 1 kDa; Spectrum Laboratories, Laguna Hills, CA,
SA) against DDW for 24 h. The dialyzed products were lyophilized.
The conjugation of CSOAA was confirmed by Fourier transform
nfrared (FTIR) spectroscopy and 1H-nuclear magnetic resonance
NMR) analyses. FTIR spectra were obtained with a JASCO FTIR
200 spectrometer (JASCO Company Ltd., Hachioji, Japan) by KBr
ethod. The 1H NMR  spectra were obtained using a Varian FT 500-
Hz NMR  spectrometer (Varian Inc., Palo Alto, CA, USA). Samples
15 mg/ml) were dissolved in DMSO-d6. The molar substitution
MS) of CSOAA, which is total number of moles of reacted AA per
ne mole of CSO, was determined by integration of the values of
he proton peaks from the 1H NMR  spectra. MS  of CSOAA was
btained using a linear regression line generated from standard
amples with various molar ratios between AA and CSO (0.5:1, 1:1,
:1, 3:1, and 4:1). The standard samples were prepared by homoge-
eously mixing CSO and AA in DDW/tetrahydrofuran (THF) mixtureof Pharmaceutics 441 (2013) 373– 380
(1:1, v/v). THF was  removed by evaporation and the resultant was
lyophilized. The ratio of integration area (1.23/1.81 ppm) of each
standard sample was  calculated.
2.3. Preparation and characterization of nanoparticles
To investigate the self-assembly behavior of CSOAA, the critical
micelle concentration (CMC) of CSOAA was determined by using
pyrene as a fluorescence probe. The fluorescence emission spec-
trum of pyrene (6 × 10−7 M)  was  recorded at 360–450 nm in the
CSOAA concentration range from 10−4 to 1 mg/ml. The excitation
wavelength was  334 nm and the slit openings for excitation and
emission were set at 10 and 3 nm,  respectively. The intensity ratio
of the first peak (I1, 373 nm)  to the third peak (I3, 384 nm)  was
calculated to determine the CMC.
Blank self-assembled nanoparticles were prepared by dissolving
CSOAA in DDW, vortexing for 15 min, and filtering through a 0.2-
m syringe filter (Minisart RC 15; Sartorius Stedim Biotech GmbH,
Goettingen, Germany).
DOX base was used as a hydrophobic drug and encapsulated
into the CSOAA nanoparticles by a solvent evaporation method.
To prepare DOX base according to a reported method (Cho et al.,
2012b), DOX HCl was reacted with triethylamine in DMSO for 12 h,
and then lyophilized. To make DOX-loaded nanoparticle, DOX base
(1 mg)  was dissolved in 1 ml DMSO and DDW mixture (1:1, v/v).
CSOAA (7.5 mg)  was  added to that mixture and vortexed for 10 min.
The solvent was  evaporated under a nitrogen gas stream for 4 h
at 70 ◦C. DOX-loaded CSOAA-based self-assembled nanoparticles
were obtained by resuspending the polymer and drug composite
film with 1 ml  DDW. That suspension was gently stirred for 15 min
and further heated at 70 ◦C for 15 min. Unloaded drug was elimi-
nated with a 0.22-m syringe filter.
The encapsulation efficiency (EE) of the DOX  in nanoparti-
cles was determined by disrupting DOX-loaded nanoparticles with
100× the volume of DMSO. DOX was analyzed quantitatively by
Waters high-performance liquid chromatography (HPLC) system
(Waters Co., Milford, MA,  USA), equipped with a reversed-phase C-
18 column (Xbridge RP18, 250 mm × 4.6 mm,  5 m; Waters Co.),
a separation module (Waters e2695), and a fluorescence detec-
tor (Waters 2475). The mobile phase consisted of 0.1 M sodium
acetate buffer (pH 4.0, adjusted with acetic acid) and acetonitrile
(71:29, v/v), and the eluent was  monitored at excitation and emis-
sion wavelengths of 470 nm and 565 nm,  respectively, with a flow
rate of 1.0 ml/min. The injection volume for drug analysis was  20 l.
The EE value was calculated using the following equation:
EE (%) = actual amount of DOX in nanoparticle
theoretical amount of DOX in nanoparticle
× 100. (1)
The mean diameter and zeta potential values of the blank
nanoparticles and DOX-loaded nanoparticles were measured by
a dynamic light scattering (DLS) method (ELS-Z, Photal; Otsuka
Electronics Co. Ltd., Osaka, Japan). The morphological shapes of
self-assembled nanoparticles were observed under transmission
electron microscopy (TEM; LIBRA 120; Carl Zeiss, Oberkochen,
Germany). The samples were placed on a copper grid coated with
carbon film, dried at 20 ◦C, and photographed.
2.4. In vitro DOX release
In vitro release studies were performed in phosphate-buffered
saline (PBS; pH 5.5, 6.8, and 7.4, adjusted with phosphoric
acid) at 37 ◦C. DOX-loaded CSOAA-based nanoparticles (150 l)
were placed in a mini GeBA-flex tube (molecular weight cut-
off = 12–14 kDa). That tube was then transferred to 10 ml  release
medium and kept in the horizontal shaker at 37 ◦C and 50 rpm
of rotation speed. An aliquot (0.2 ml)  of the release medium was




































eriodically collected (at 1, 2, 3, 4, 6, 9, 12, 24, 48, 72, 96, 120, and
44 h) and the same volume of fresh medium was  replaced. The
eleased DOX was quantitatively analyzed by HPLC system.
.5. In vitro cytotoxicity of CSOAA
FaDu cells were purchased from the Korean Cell Line
ank (Seoul, Korea). These cells were cultured in MEM  con-
aining 10% FBS, 100 U/ml penicillin, and 100 g/ml strepto-
ycin at 37 ◦C under 5% CO2 atmosphere and 95% relative
umidity. The cytotoxicity of CSOAA was determined by
 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-
ulfophenyl)-2H-tetrazolium (MTS)-based assay. Cells were seeded
n 96-well plates at a density of 1.0 × 104 cells per well. After
4 h of incubation, the cell culture medium was  replaced with
00 l medium containing various concentrations (5–500 g/ml)
f CSOAA and incubated for 12 and 24 h. After discarding the cul-
ure medium, cells were treated with the MTS-based CellTiter 96
Queous One Solution Cell Proliferation Assay Reagent (Promega
orp., Madison, WI,  USA) at 37 ◦C for 4 h, according to the
anufacturer’s protocol. The spectrophotometric absorbance of
amples was measured at a wavelength of 490 nm using an EMax
recision Microplate Reader (Molecular Devices, Sunnyvale, CA,
SA).
.6. In vitro cellular uptake
Cellular uptake efficiency was evaluated by flow cytometry
nalysis. FaDu cells were seeded in 6-well plates at a density of
 × 105 cells per well and grown overnight at 37 ◦C. The culture
edium was then removed, and the cells were incubated with free
OX or the DOX-loaded CSOAA-based nanoparticles at an equiv-
lent DOX concentration (50 g/ml) for 1 h. After washing with
BS (pH 7.4) at least three times, the cells were detached and cen-
rifuged. The supernatant was then removed and the cell pellets
ere resuspended with PBS containing 2% (v/v) FBS. DOX uptake
as analyzed using a Calibur fluorescence-activated cell sorter
quipped with CELLQuest software (Becton Dickinson Biosciences,
an Jose, CA, USA).me of CSOAA.
2.7. In vivo anti-tumor efficacy
Female BALB/c nude mice (5 weeks old; Charles River) were
used to prepare a tumor-bearing mouse model for evaluating anti-
cancer efficacy. Mice were maintained in a light-controlled room
kept at a temperature of 22 ± 2 ◦C and a relative humidity of 55 ± 5%
(Animal Center for Pharmaceutical Research, College of Pharmacy,
Seoul National University, Seoul, Korea). Experimental protocols
used were approved by the Animal Care and Use Committee of
the College of Pharmacy, Seoul National University. BALB/c nude
mice bearing FaDu tumors were prepared by subcutaneous injec-
tion of 3 × 106 cells in the right back. Tumor size was  measured
with Vernier calipers and tumor volume (mm3) was calculated
according to the following formula: volume = 0.5 × longest diame-
ter × shortest diameter2. Measuring tumor volume and weighing
body weight started 10 days post-inoculation, when the tumor
volume reached about 50–100 mm3. The mice were divided into
three groups: control, DOX solution, and DOX-loaded CSOAA-based
nanoparticles. Both DOX solution and DOX-loaded nanoparticles
were injected intravenously at a dose of 25 mg/kg on days 6, 8, 11,
and 13. The tumor volume and body weight were monitored for 18
days.
2.8. Statistical analysis
Statistical analyses were performed using analysis of variance.
All experiments were performed at least three times and the data
are presented as mean ± standard deviation (SD).
3. Results
3.1. Synthesis and characterization of CSOAA
The CSOAA conjugate was  synthesized by EDC- and NHS-
mediated amide bond formation between the carboxylic group of
AA and the amine group of CSO. The synthesis scheme is shown
in Fig. 1. EDC can react with the carboxylic group of AA to form an
EDC active ester, and the NHS ester intermediate forms rapidly. The
intermediate can then react with the primary amine of CSO to form
an amide bond.
















Fig. 2. FTIR spectra of AA, CSO, and CSOAA.
The structural characterization of CSOAA was performed using
TIR and 1H NMR. The FTIR spectrum (Fig. 2) confirmed the syn-
hesis of the CSOAA conjugate. Absorption bands of CSO at 1591
nd 1643 cm−1 were assigned to N H bending of the deacetylated
mine ( NH2) and carbonyl stretching of a non-deacetylated amide
NHC OCH3; amide I band), respectively. After the reaction, the
mine peak at 1591 cm−1 of CSO disappeared and a new absorption
and at 1558 cm−1 in the spectrum of CSOAA was observed, which
as associated with the formation of a new amide bond (amide
I band). Additionally, absorption bands at 2918 and 2851 cm−1 of
SOAA represented stretching vibrations of the acyl chain, CH2
nd CH3 of AA, respectively. The conjugation of AA to CSO was also
onfirmed by 1H NMR  analysis (Fig. 3). The 1H NMR  spectrum of
SOAA exhibited proton signals for both CSO and AA. Although the
roton peaks of the glucosamine ring of CSO overlapped with the
MSO-d6 solvent, the proton peaks at 0.86 and 1.23 ppm indicated
Fig. 3. 1H NMR  spectrum of CSOAA. CSOAA was dFig. 4. The correlationship between the ratio of integration area (1.23/1.81 ppm)
and  molar ratio of AA/CSO based on their physical mixture. Each point represents
the  mean ± SD (n = 3).
a terminal methyl group ( CH3) and an alkyl chain ( CH2 ) of
AA, respectively. Furthermore, a new proton peak of CH2 of AA
linked with a carbonyl group was seen at 2.07 ppm in the 1H NMR
spectrum of the CSOAA conjugate, whereas that peak was  absent in
the spectrum of a physical mixture of CSO and AA (Supplementary
Fig. 1S). This result indicated that AA was successfully conjugated
to the CSO backbone via amide bond formation.
To calculate the MS  of CSOAA, the homogeneous physical mix-
tures of CSO and AA (at different molar ratios) were prepared
as standard samples and analyzed by 1H NMR. As shown in
Fig. 4, the linear regression line was  generated by plotting the
ratio of integration area between peak of the alkyl chain pro-
tons of AA (ı = 1.23 ppm; CH2 ) and the N-acetyl protons of
CSO (ı = 1.81 ppm; NH CO CH3) according to the molar ratio of
AA/CSO. The MS  of CSOAA was  1 (mole of AA/mole of CSO), cal-
culated from the equation of regression line with its 1H NMR
integration ratio (1.23/1.81 ppm), when the initial molar ratio
issolved in DMSO-d6 for 1H NMR  analysis.






































Fig. 6. Morphology and size distribution of DOX-loaded CSOAA-based nanopar-
ticles. (a) The size distribution of DOX-loaded CSOAA-based nanoparticles was
determined by dynamic light scattering. The CSOAA:DOX weight ratio was 7.5:1.
(b) TEM images of DOX-loaded CSOAA-based nanoparticles were shown. Bar lengths
are  500 (left) and 200 (right) nm,  respectively.
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Fig. 7. In vitro DOX release profiles from CSOAA-based self-assembled nanopar-ig. 5. Determination of the CMC  of CSOAA. Fluorescence intensity ratio (I373/I384)
as  plotted against CSOAA concentration.
AA/CSO) was  3 in the conjugation reaction. The chemical yield of
SOAA was 61.2%.
The self-assembly behavior of CSOAA in the aqueous phase was
nvestigated by fluorescence measurements, using pyrene as a flu-
rescence probe (Fig. 5). CMC  can be determined by measuring the
ntensity ratio (I1/I3) between the first (373 nm)  and third (384 nm)
mission peaks of pyrene according to the CSOAA concentration. As
hown in Fig. 5, the CMC  of CSOAA was 1.42 g/ml.
.2. Preparation and characterization of CSOAA-based
elf-assembled nanoparticles
Blank self-assembled nanoparticles (without drug loading) were
repared by dissolving CSOAA in the aqueous solution. The for-
ation of nanoparticles was confirmed by measuring particle size
nd zeta potential values. To load DOX into the CSOAA-based
anoparticles, a solvent evaporation method was used. The mean
iameter and zeta potential values were measured by DLS and are
hown in Table 1. The mean diameter of blank nanoparticles was
maller than that of DOX-loaded nanoparticles (73.67 ± 3.91 nm
s. 130.00 ± 5.76 nm). The polydispersity index of the DOX-loaded
anoparticles was 0.23 ± 0.02, indicating a narrow size distribu-
ion of nanoparticles (Fig. 6a). The zeta potential value was also
ncreased slightly after loading DOX into the nanoparticles (from
.58 ± 0.62 mV  to 12.98 ± 0.55 mV). The spherical shape of the DOX-
oaded CSOAA-based nanoparticles was observed by TEM (Fig. 6b).
o aggregation of CSOAA-based nanoparticles was  observed in that
mage. The loading amount of DOX in the nanoparticles was  mea-
ured by HPLC analysis and the EE was 53.12 ± 2.60%.
.3. In vitro DOX release
DOX release patterns from nanoparticles were investigated
nder different pH conditions (pH 5.5, 6.8 and 7.4) at 37 ◦C (Fig. 7).
OX release from the CSOAA-based nanoparticles was monitored
or 6 days. Sustained drug release was observed and it was depend-
nt on the pH of the release medium. About 30% of DOX was
eleased in the first 12 h under all pH conditions. After that,
he amounts of DOX released from CSOAA-based nanoparticles
ncreased as the pH value of the releasing medium decreased. After
 days, DOX was completely released at pH 5.5; in contrast, 78%
nd 64% of DOX was released at pH 6.8 and 7.4, respectively.
ticles. Drug release profiles from CSOAA:DOX = 7.5:1 formulation at different pH
conditions (pH 5.5, 6.8, and 7.4) are shown. Each point represents the mean ± SD
(n  = 3).
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Table 1
Characteristics of CSOAA-based nanoparticles.
Formulation Mean diameter (nm, mean ± SD) Polydispersity index Zeta potential (mV) Encapsulation efficiency (%)
Blank nanoparticles 73.67 ± 3.91 0.32 ± 0.01 7.58 ± 0.62 –
CSOAA:DOX (7.5:1) 130.00 ± 5.76 0.23 ± 0.0
Values are presented as mean ± SD (n ≥ 3).
Polymer concentration (µg/ml)







































ig. 8. In vitro cytotoxicity tests of CSOAA in FaDu cells. Various concentrations of
SOAA were incubated for 12 and 24 h in FaDu cells. Cell viability (%) was  determined
y  an MTS-based assay. Each point represents the mean ± SD (n = 4).
.4. In vitro cytotoxicity test
To examine the cytotoxicity of CSOAA, cell viability was  mea-
ured in FaDu cells, a head and neck cancer cell line. The cells were
reated with various concentrations of CSOAA for 12 and 24 h. As
hown in Fig. 8, FaDu cell viability (%) was over 90% for all CSOAA
oncentrations tested. Thus, it can be concluded that CSOAA had no
evere toxicity for FaDu cells..5. In vitro cellular uptake study
The cellular uptake efficiency of DOX in FaDu cells was investi-
ated by flow cytometry. Fluorescence intensity was  assumed to be
ig. 9. Cellular uptake efficiency of DOX analyzed by flow cytometry. DOX solution and DOX
roup  (black: control, red: DOX solution group, green: DOX-loaded nanoparticle group). (Fo
o  the web version of this article.)2 12.98 ± 0.55 53.12 ± 2.60
proportional to the amount of DOX internalized into the cells. Fig. 9
shows that higher amount of DOX from CSOAA-based nanoparticles
was taken up into the cells than from the DOX solution group.
3.6. In vivo anti-tumor efficacy
In vivo anti-tumor efficacy of DOX-loaded nanoparticles was
assessed in a FaDu tumor-bearing mouse model. DOX solution
and DOX-loaded CSOAA-based nanoparticles were injected intra-
venously on days 6, 8, 11, and 13. Tumor volume (mm3) and body
weight (g) were monitored for 18 days. As shown in Fig. 10a, tumor
growth inhibition in the DOX-loaded nanoparticle-treated group
was significantly higher than in either the DOX  solution-treated
group or the control group (p < 0.05). After 18 days of treatment
with DOX solution or DOX-loaded nanoparticles, tumor volumes
were 44.63 ± 9.02% and 25.24 ± 5.61% of that for control group.
No significant difference in body weight change was  observed
among the three groups; control, DOX solution-, and DOX-loaded
nanoparticle-treated groups (Fig. 10b).
4. Discussion
In this study, CSOAA was  successfully synthesized as a
hydrophobically modified CSO for the preparation of self-
assembled nanoparticles. The synthesis of CSOAA conjugate was
confirmed by 1H NMR  analysis, but accurate substitution ratio (AA
to CSO) might not be obtained from 1H NMR  spectrum of CSOAA.
From 1H NMR  analysis of CSOAA, the proton peak of the glu-
cosamine ring of CSO could be overlapped with the solvent peak
and deacetylation degree of CSO was  not obviously determined.
Because of these limitations, the correlation between the integra-
tion ratio (1.23/1.81 ppm) and molar ratio of AA/CSO, based on
physical mixture, was  evaluated in this investigation (Fig. 4). With
the input of the integration ratio (1.23/1.81 ppm) of CSOAA conju-
gate into this regression line, the stoichiometric ratio of CSOAA can
-loaded nanoparticles were incubated for 1 h. The colors indicate each experimental
r interpretation of the references to color in this figure legend, the reader is referred
U. Termsarasab et al. / International Journal 
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Fig. 10. Anti-tumor efficacy test of DOX-loaded CSOAA-based nanoparticles in a
FaDu tumor-bearing BALB/c nude mouse model. (a) Tumor volume (mm3) profiles



























anoparticles were injected intravenously on days 6, 8, 11, and 13. Each point indi-
ates the mean ± SD (n ≥ 4). (b) Body weight (g) was monitored. Each point indicates
he  mean ± SD (n ≥ 4). *P < 0.05 vs.  control group; +P < 0.05 vs.  DOX solution group.
e determined more accurately. It is assumed that established assay
Fig. 4) could help identify the synthesis of CSOAA and calculate
ubstitution ratio. The CMC  value is also an important character-
stic of micellar structured nanoparticle. The CMC  value of CSOAA
as significantly lower than those of low-molecular-weight sur-
actants in water (Lee et al., 1998). It can be concluded that CSOAA
an form stable nanoparticulate structures at its low concentration
fter dilution with a large volume of body fluids.
The CSOAA synthesized could readily produce self-assembled
anoparticles in aqueous solution because of its amphiphilic prop-
rty. The AA part could constitute an internal hydrophobic core,
hile CSO could provide a hydrophilic outer shell of the nanopar-
icles. The DOX-loaded CSOAA-based self-assembled nanoparticles
ere prepared by a solvent evaporation method. This method can
rovide several advantages over dialysis methods, such as the short
reparation period and high drug loading efficiency (Park et al.,
004). DOX-loaded CSOAA-based nanoparticles exhibited <200 nm
f mean diameter and narrow size distribution, high drug encap-
ulation efficiency, and negligible cytotoxicity. Because of these
roperties, it is assumed that DOX-loaded CSOAA-based nanopar-
icles can effectively accumulate in the tumor region via the EPR
ffect and exhibit reduced uptake by RES (Maeda et al., 2000; Yuan
t al., 1995).
The sustained and pH-dependent drug release patterns from
he CSOAA-based nanoparticles developed were observed (Fig. 7).of Pharmaceutics 441 (2013) 373– 380 379
Sustained drug release can lead to reduced in vivo drug clear-
ance and maintenance of effective drug concentrations for tumor
growth inhibition. Additionally, larger amount of DOX was released
at acidic pH, simulating the endocytic compartment of cancer cells,
compared with normal pH condition (pH 7.4). This difference may
have been due to the slack structure of the nanoparticle, following
protonation of amino groups in CSO and the higher solubility
of DOX at an acidic pH. These results indicate that DOX-loaded
CSOAA-based nanoparticles can be highly accumulated and release
a large amount of drug in tumor tissues, with less DOX delivery to
non-tumor regions. Moreover, enhanced drug release at pH 5.5 can
imply endosomal escape of the drug and its improved transport to
the cell nucleus.
As shown in Fig. 9, larger amount of DOX from nanoparticle-
treated group was taken up to the cells compared to that
from DOX solution group. This result may  be explained by the
interaction between the positively charged surface of the CSOAA-
based nanoparticle and the negatively charged cellular membrane,
and subsequent endocytosis of nanoparticles (Chavanpatil et al.,
2006; Lee et al., 2011; Zauner et al., 1998). Furthermore, fatty
acid-modified CS nanoparticles have been reported to form self-
assembled nanoparticles with a multi-hydrophobic core (You et al.,
2007). A hydrophobic minor core may  help the internalization of
nanoparticles into the cells by inserting fatty acids into the cell
membrane.
FaDu cells were selected as a head and neck cancer cell line
for this investigation. As shown in Fig. 10a, DOX-loaded CSOAA-
based nanoparticles exhibited significant inhibitory effects on FaDu
tumor growth, compared with both the control and DOX  solution-
treated groups. The physicochemical properties of drug-loaded
nanoparticles, sustained drug release, and passive targeting, via
mainly an EPR effect, may explain the efficient tumor growth inhibi-
tion by DOX-loaded CSOAA-based nanoparticles. In conclusion, the
self-assembled CSOAA-based nanoparticle developed can be used
as an anti-cancer drug delivery system, especially for head and neck
cancer therapy.
5. Conclusions
CSOAA was synthesized for the preparation of self-assembled
nanoparticles for DOX delivery. Its CMC  value was  relatively low
and it could form self-assembled nanoparticles in an aqueous
environment with a narrow size distribution. DOX-loaded CSOAA-
based nanoparticles showed a sustained and pH-dependent drug
release profile. It seemed that the nanoparticulate structure and
drug release profile of the nanoparticles influenced on the cel-
lular uptake and anti-tumor activity. DOX-loaded CSOAA-based
nanoparticles significantly inhibited FaDu tumor growth in vivo.
Considering all experimental results in this study, CSOAA-based
self-assembled nanoparticles may  be a promising carrier for anti-
cancer drug delivery.
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a  b  s  t  r  a  c  t
Arachidyl  chitosan  (chitosan  oligosaccharide–arachidic  acid;  CSOAA)-based  self-assembled  nanoprobes
for  magnetic  resonance  imaging  (MRI)  of  neoplastic  lesions  was  developed  and  evaluated  in vitro.
Diethylenetriaminepentaacetic  dianhydride  (DTPA)  was  conjugated  to  chitosan  oligosaccharide  (CSO)
and Gd3+ was  chelated  to  the  resulting  ligand.  DTPA  conjugation  and  Gd3+ chelation  were  confirmed  pri-
marily  by  Fourier  transform  infrared  spectroscopy  (FT-IR)  and  zeta  potential  measurement.  A spherical
nanoprobe  of around  150 nm  mean  diameter  in  the  tested  concentration  range  was formed  in an  aque-
ous  environment  by simple  dissolution.  The  critical  aggregation  concentration  (CAC)  of the CSOAA-based
nanoprobe  was  3.86  g/ml,  indicating  its  stability  after  dilution  in  body  fluid.  The nanoprobe  had  negli-ead and neck cancer
agnetic resonance imaging
anoprobe
gible  toxicity  in  head  and  neck  cancer  cell  lines  (Hep-2  and  FaDu  cells).  The  amount  of  Cy5.5-labeled
nanoprobe  taken-up  by  cells,  as observed  by confocal  laser scanning  microscopy  (CLSM),  increased
according  to  incubation  time  (up to 12  h).  A  phantom  study  showed  a T1-positive  contrast-enhancing
effect  of  the  developed  CSOAA-based  nanoprobe,  compared  to that  of the  commercial  formulation  (Gd-
DTPA;  Magnevist).  These  results  indicate  that  the  CSOAA-based  nanoprobe  can  be  used  for  efficient  MR
imaging  of neoplastic  cells.. Introduction
Alongside innovations in drug delivery for cancer therapy,
maging techniques for cancer diagnosis have also evolved.
rogress in imaging agents and apparatus used for magnetic
esonance imaging (MRI), computed tomography (CT), positron
mission tomography (PET), single-photon emission computed
omography (SPECT) and ultrasound have contributed to more
ccurate diagnosis of cancer. MRI  is one of the most powerful
maging techniques for diagnosis and has several advantages,
uch as high resolution of specific tissues and organs and deep
enetration into the soft tissues [1–3]. MRI  can provide abundant
nformation on the anatomical and physiological state of the body
4]. Additionally, contrast agents are used to improve sensitivity
esulting from the interaction with surrounding water protons
nd shortening of the proton relaxation time to enhance contrast
5]. Contrast agents can be classified into the T1-weighted type
paramagnetic gadolinium chelates) and the T2-weighted type
∗ Corresponding author. Tel.: +82 2 880 7870; fax: +82 2 873 9177.
E-mail address: ddkim@snu.ac.kr (D.-D. Kim).
1 These authors are contributed equally.
927-7765/$ – see front matter ©  2013 Elsevier B.V. All rights reserved.
ttp://dx.doi.org/10.1016/j.colsurfb.2013.03.058© 2013 Elsevier B.V. All rights reserved.
(superparamagnetic iron oxide nanoparticles; SPION), which
could enhance the contrast of regions of interest positively or
negatively, respectively [2,3]. In particular, the T1 contrast agents
(paramagnetic Gd3+ chelates) have several advantages: high mag-
netic moment, suitable electron relaxation time, and a positive
contrast enhancing effect [2,6]. Clinically relevant Gd3+ chelates
are as follows [6]: Gd-diethylenetriaminepentaacetic acid (Gd-
DTPA), Gd-1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetraacetic
acid (Gd-DOTA), and Gd-10-(2-hydroxypropyl)-1,4,7,10-tetra-
azacyclododecane-1,4,7-triacetic acid (Gd-HP-DO3A). Although
these Gd3+ chelates have been used successfully clinically, they
have some problems; reduction of relaxivity (r1) by chelation
(mainly due to the decreased number of coordination sites for
water proton exchange), lack of specificity for certain tissues or
organs, and rapid clearance from the blood due to renal excre-
tion [7,8]. Therefore, acquisition of enough spatial information
on long-term application and disease targeting is difficult. It is
expected that development of polymeric nanoparticles-based
imaging agents will solve these problems.Recently, polysaccharide-based nanoprobes for MR  imaging
have been investigated [4,9–11]. Various MR  imaging probes
based on chitosan or its derivatives have been developed [12–14].
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ancer diagnosis, but chitosan nanoparticles can accumulate in
he tumor region after intravenous injection, mainly due to the
nhanced permeability and retention (EPR) effect. In our previous
tudy [15], chitosan oligosaccharide–arachidic acid (CSOAA), as an
mphiphilic CSO derivative, was synthesized and used to prepare
elf-assembled nanoparticles. A hydrophobic anti-cancer drug was
ncorporated into the hydrophobic internal cavity of nanoparticles
nd injected intravenously into a head and neck cancer xenografted
ouse model to evaluate in vivo anti-tumor efficacy. Herein, we
eport the development and in vitro evaluation of CSOAA-DTPA-Gd
anoprobes for MR  imaging of cancer. DTPA was  conjugated to CSO,
fter which Gd3+ was chelated to the DTPA ligand. It is expected
hat self-assembled CSOAA can form a nano-sized MRI probe (mean
iameter, ∼150 nm)  in an aqueous environment, and thus can act
s a useful MR  imaging probe for cancer diagnosis.
. Materials and methods
.1. Materials
Chitosan oligosaccharide (average molecular weight = 5 kDa,
egree of deacetylation >90%) was purchased from
itto Life Co., Ltd. (Seoul, Korea). Arachidic acid (AA),
-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC),
-hydroxysuccinimide (NHS), pyrene, diethylenetriamine-
entaacetic dianhydride (DTPA), and gadolinium (III) chloride
exahydrate (GdCl3•6H2O) were purchased from Sigma Chemical
o. (St. Louis, MO,  USA). Cy5.5 NHS ester was purchased from
mersham Biosciences (Piscataway, NJ, USA). Dulbecco’s modified
agle’s medium (DMEM), minimum essential medium (MEM),
enicillin, streptomycin, and heat-inactivated fetal bovine serum
FBS) were obtained from Gibco Life Technologies, Inc. (Grand
sland, NY, USA). All other chemicals were of reagent grade and
sed without further purification.
.2. Synthesis of CSOAA-DTPA-Gd
CSOAA was synthesized according to our previous method [15].
n brief, CSO (0.2 mmol) and AA (0.6 mmol) were dissolved sep-
rately in 20 ml  dimethyl sulfoxide (DMSO) at 50 ◦C for 15 min.
he carboxyl groups of AA were activated by adding EDC and NHS
molar ratio for AA = 1.5:1) and stirring for 30 min at room tempera-
ure. The activated AA solutions were added to the CSO solution for
 min, then allowed to react for a further 12 h, after which double-
istilled water (DDW) at a volume ratio of 10% was added. The pH
f mixed solutions was adjusted to 3.5 with 1 N HCl and stirred for
0 min. The solution was precipitated with acetone (ten times the
olume of the mixture, v/v) and centrifuged at 7500 rpm for 30 min
o eliminate unreacted AA. The precipitation step was  repeated
hree times. After precipitation, the precipitates were dispersed
ith DDW and dialyzed against DDW with a dialysis membrane
molecular weight cut-off: 1 kDa, Spectrum Laboratories, Laguna
ills, CA, USA) for 1 day. Dialysis products were obtained by freeze-
rying.
DTPA was conjugated to CSO by amide bond formation between
he carboxylic group of DTPA and the amine group of CSO. DTPA
0.1 mmol) was dissolved in DDW (15 ml), and EDC (0.2 mmol) and
HS (0.2 mmol) were added. After stirring for 30 min, the solu-
ion was slowly added to CSOAA (0.02 mmol) solution in DDW
20 ml). It was further stirred for 12 h at room temperature and dia-
yzed with a dialysis membrane (molecular weight cut-off: 3.5 kDa)
gainst DDW for 3 days. CSOAA-DTPA was obtained by lyophiliza-
ion. For Gd3+ chelation, GdCl3•6H2O (0.05 mmol) dissolved in 5 ml
f DDW was slowly added to CSOAA-DTPA (0.01 mmol) dissolved
n 30 ml  DDW and the pH was adjusted to 7 by 1 N NaOH. It wasB: Biointerfaces 109 (2013) 280– 286 281
stirred for 24 h and dialyzed for 3 days against DDW to remove free
Gd3+. CSOAA-DTPA-Gd was  obtained by freeze-drying. DTPA con-
jugation to CSOAA was identified by 1H NMR  analysis (500 MHz).
CSOAA-DTPA was solubilized in deuterium oxide (D2O) for 1H NMR
analysis. DTPA conjugation and Gd3+ chelation were also confirmed
by FT-IR analysis with a JASCO FT-IR 4200 spectrometer (JASCO
Company Ltd., Hachioji, Japan). Gd content in the CSOAA-based
nanoprobe was determined by an inductive coupled plasma-atomic
emission spectrometer (ICP-AES, Optima 4300 DV, PerkinElmer
Inc., Wellesley, MA,  USA).
2.3. Characteristics of the CSOAA-based nanoprobe
To produce CSOAA-based nanoprobes, CSOAA-DTPA-Gd was
solubilized in DDW, phosphate buffered saline (PBS, pH 7.4) or
50% (v/v) FBS solution (in PBS pH 7.4). After dissolving at a
predetermined concentration, the sample was  sonicated using a
probe-type sonicator (Vibra-Cell VC 750 ultrasonic processor, Son-
ics & Materials, CT, USA) for 1 min. Mean diameter, polydispersity
index, and zeta potential values of the nano-sized probe were mea-
sured using a light-scattering spectrophotometer (ELS-Z; Otsuka
Electronics, Tokyo, Japan) according to the manufacturer’s proto-
col. The morphology of the CSOAA-based nanoprobe was observed
by transmission electron microscopy (TEM). The nanoprobes were
placed on copper grids with films. After air-drying for 10 min, they
were observed by TEM (JEM 1010; JEOL, Tokyo, Japan). The scale
bar in the images represents 1 m.  Critical aggregation concentra-
tion (CAC) of the CSOAA-based nanoprobe was determined using
a fluorescence spectrophotometer with pyrene as a hydrophobic
substance. Pyrene dissolved in acetone (2 × 10−6 M)  was prepared
and 0.3 ml  of that solution was transferred to each 1.5 ml  tube.
Acetone was evaporated under a gentle nitrogen (N2) gas stream
for 1 h at 60 ◦C. The nanoprobe solution in DDW (1 ml), the con-
centration of which ranged from 0.1–1000 g/ml, was added to
each tube to make a 6 × 10−7 M pyrene concentration. The emission
spectrum (310–550 nm)  was obtained at a fixed 334 nm excitation
wavelength with a fluorescence spectrometer FP-6500 (JASCO Co.,
Tokyo, Japan).
2.4. In vitro cytotoxicity of the nanoprobe
Hep-2 and FaDu cells were purchased from Korean Cell Line
Bank (KCLB, Seoul, Korea). Hep-2 cells were cultured with DMEM
supplemented with 10% FBS, 100 U/ml penicillin, and 100 g/ml
streptomycin, and FaDu cells were cultured with MEM  containing
10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin, in a 5%
CO2 atmosphere with 95% relative humidity at 37 ◦C. After Hep-2
and FaDu cells reached 70–80% confluency, they were trypsinized
and seeded in a 96-well plate at a density of 1.0 × 104 per well.
After incubation for 24 h, the culture medium was removed. After
12 and 24 h incubation of CSOAA-DTPA and CSOAA-DTPA-Gd
(15–300 g/ml) with both cell types at 37 ◦C, 5% CO2 and 95% rel-
ative humidity, the cell viability (%) was determined using the
MTS-based CellTiter 96 AQueous One Solution Cell Proliferation
Assay Reagent (Promega Corp., WI,  USA) at 37 ◦C for 4 h, accord-
ing to the manufacturer’s protocol. The absorbance at 490 nm was
measured using an Emax Precision Microplate Reader (Molecular
Devices, Sunnyvale, CA, USA).
2.5. In vitro cellular uptake
To monitor the intracellular uptake of nanoprobes, Cy5.5, a near-
infrared fluorescence (NIRF) dye for observation by confocal laser
scanning microscopy (CLSM), was conjugated to a CSO backbone by
amide bond formation. The CSOAA-DTPA conjugate (100 mg)  was
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y5.5 NHS ester (0.2 mg)  dissolved in 0.02 ml  DMSO was slowly
dded to a CSOAA-DTPA-containing buffer and stirred for 3 h at
oom temperature. Free Cy5.5 was removed by dialysis against
DW for 3 days. The final product was obtained by lyophilization.
or Gd3+ chelation, the previously described synthesis method was
sed. In brief, GdCl3•6H2O (0.05 mmol) dissolved in 5 ml  DDW was
lowly added to Cy5.5-CSOAA-DTPA (0.01 mmol) dissolved in 30 ml
DW and the pH was adjusted to 7 using 1 N NaOH. The solution
as stirred for 24 h and dialyzed for 3 days against DDW to remove
ree Gd3+. Cy5.5-CSOAA-DTPA-Gd was obtained by freeze-drying.
he Cy5.5 content in the Cy5.5-labeled CSOAA-based nanoprobe
as determined by measuring absorbance at 650 nm with a UV/vis
pectrophotometer (Emax Precision Microplate Reader, Molecular
evices, Sunnyvale, CA, USA). Linearity was established in the range
–25 g/ml Cy5.5.
After Hep-2 and FaDu cells acquired 70–80% confluency, the
ells were trypsinized and seeded onto culture slides (BD Falcon,
edford, MA)  at a density of 1.0 × 105 per well (surface area of
.7 cm2 per well, four-chamber slides) and incubated for 24 h at
7 ◦C. The Cy5.5-labeled nanoprobe (1 mg/ml) was incubated for
.5, 8 and 12 h at 37 ◦C. The cells were then washed with phosphate-
uffered saline (PBS, pH 7.4) at least three times and fixed with a 4%
ormaldehyde solution for 5 min. VECTASHIELD mounting medium
ith 4′,6-diamidino-2-phenylindole (DAPI) (H-1200; Vector Labo-
atories, Inc., Burlingame, CA, USA) was added to stain nuclei and
revent the fading of fluorescence. The preparations were observed
y CLSM (LSM 710; Carl-Zeiss, Thornwood, NY, USA).
.6. In vitro MRI  study
All MRI  studies were performed with a 4.7-T MRI  apparatus
Bruker BioSpec 47/40, Karlsruhe, Germany). T1 contrast intensi-
ies of Gd-DTPA (Magnevist®, Bayer Schering Pharma AG, Berlin,
ermany) and the CSOAA-based nanoprobe were scanned at
–100 M Gd concentrations. Specific parameters were as follows:
cho time (TE) = 6.5 ms,  repetition time (TR) = 1000 ms,  field of view
FOV) = 5 × 4 cm,  matrix = 128 × 128, slice thickness = 2 mm.












+ R1 [M] (1)
here (1/T1)obs and (1/T1)d are the relaxation rates of the protons
n the presence and absence of paramagnetic species (Gd), respec-
ively, and [M]  is the concentration of the paramagnetic species
Gd).
.7. Data analysis
All experiments were performed at least three times and the
ata were represented as mean ± standard deviation (SD).
. Results and discussion
.1. Synthesis of the CSOAA-based nanoprobe
CSOAA was synthesized, as an amphiphilic CSO derivative, to
repare self-assembled nanoparticles according to the reported
ethod [15]. CSOAA was synthesized by amide bond formation
etween the carboxylic group of AA and the amine bond of CSO
y an EDC-coupled reaction (Fig. 1A). Synthesis was identified by
H NMR  analysis. Though the proton peaks for the glucosamine
ing of CSO overlapped those of the solvent, the proton peaks at
.86 and 1.23 ppm indicated that the terminal methyl group ( CH3)
nd alkyl chain ( CH2 ) of AA were present [15]. In particular, theB: Biointerfaces 109 (2013) 280– 286
proton peak of CH2 of AA linked with the carbonyl group with-
out conjugation (2.21 ppm) was  shifted after amide bond formation
(2.16 ppm). According to our previous report [15], conjugation of
AA to the CSO backbone was  also confirmed by FT-IR analysis. In
particular, the amide II band was  shifted from 1591 cm−1 in the
CSO spectrum to 1558 cm−1 in the CSOAA spectrum. Prior to Gd
chelation, DTPA was conjugated to CSOAA, as confirmed by 1H
NMR  and FT-IR analysis. An amide bond was  formed between the
amine group of CSO and the carboxylic group of DTPA by an EDC-
coupled reaction (Fig. 1A). As shown in Fig. 1S, peaks indicating
DTPA (3.3 ppm) and CSO (2.0 ppm) were presented in the 1H NMR
spectrum of CSOAA-DTPA. The FT-IR spectra also revealed the con-
jugation of DTPA to CSOAA (Fig. 1B). The FT-IR spectrum of CSOAA
was reported in our previous study [15]. Considering the FT-IR
spectrum of CSOAA, the amide I band was shifted from 1648 cm−1
in the CSOAA spectrum to 1632 cm−1 in the CSOAA-DTPA spec-
trum (Fig. 1B). In particular, the amide II band at 1558 cm−1 in the
spectrum of CSOAA was  altered in the spectrum of CSOAA-DTPA.
Absorption intensity of the C O stretching band in CSOAA-DTPA
at 1075 cm−1 was  attenuated in the spectrum of CSOAA-DTPA-
Gd by coordination of Gd3+ to DTPA. Furthermore, the Gd content
in the CSOAA-based nanoprobe measured by ICP-AES was 5.43%
(w/w). Synthesis of CSOAA-DTPA-Gd was also evaluated by mea-
surement of zeta potential, as reported previously [4,11]. As shown
in Table 1, the zeta potential was  decreased by DTPA conjugation
from 12.50 ± 0.81 mV (CSOAA) to 9.21 ± 0.85 mV (CSOAA-DTPA). It
may  be induced by ionization of the carboxylic group of DTPA. After
chelation of Gd3+ to CSOAA-DTPA, its zeta potential was  slightly
increased to 11.19 ± 0.39 mV.  The zeta potential can be altered by
several factors, such as nanoprobe concentration, DTPA conjugation
degree, and Gd content.
3.2. Characteristics of the nanoprobe
A nano-sized CSOAA-based probe was prepared using the self-
assemble property of CSOAA. The mean diameter, polydispersity
index, and zeta potentials of the nanoprobes were measured. As
shown in Table 1, the mean diameter of the CSOAA-DTPA-Gd
nanoprobe was  146.30 ± 5.51 nm (at 1 mg/ml  concentration of the
nanoprobe) and was  around 150 nm within 5 mg/ml concentration
in DDW (Fig. 2A). Mean diameter of CSOAA-based nanoprobe (at
5 mg/ml  concentration) was  248.97 ± 6.70 and 167.70 ± 0.92 nm in
50% (v/v) FBS solution (in PBS pH 7.4) and PBS (pH 7.4), respec-
tively (Fig. 2S). The mean diameters of nanoprobes in both media
were maintained constantly for 4 h. Although the particle size of
nanoprobe in 50% FBS solution slightly increased compared to that
in DDW or PBS, it is still considered to be suitable for the cellular
uptake and passive tumor targeting. The morphology was observed
by TEM to be spherical (Fig. 2B). The CSOAA-based nanoprobe
also exhibited a narrow size distribution (Fig. 2C). The CAC value
of CSOAA was 1.42 g/ml [15] and that of CSOAA-DTPA-Gd was
3.86 g/ml (Fig. 2D); the lower value implies that the CSOAA-based
nanoprobe may  be more stable after dilution in body fluids.
Gd-DTPA (Magnevist) has a terminal elimination half-life of
about 20 min  [16]. Considering the higher molecular weight and
larger particle size of the developed polymeric nanoprobe, a
polymeric nanoprobe including Gd-DTPA likely exhibits reduced
in vivo clearance, thereby increasing its blood circulation time
compared to the commercial contrast agent (Magnevist). More-
over, the EPR effect can improve accumulation of nanoprobes in
the tumor region. In our previous report, the nano-sized poly-
meric probe exhibited MR  signal-enhancing effects in the tumor
region compared to the commercial formulation [4]. The particle
size (∼150 nm)  of the experimental nanoprobe in this study may
yield improved tumor targetability and cancer diagnosis.












Fig. 1. Synthesis and characteristics of the CSOAA-based nanoprobe. (A) Syn
.3. In vitro cytotoxicity
The cytotoxicity of the CSOAA-based nanoprobe (CSOAA-DTPA
nd CSOAA-DTPA-Gd) was evaluated in cancer cells according to
anoprobe concentration and incubation time. In this investiga-
ion, Human laryngeal and pharyngeal cancer (Hep-2 and FaDu)
ells were used. These two cell types have previously been used for
ead and neck cancer research [15,17]. CSOAA showed no severe
able 1
haracteristics of CSOAA, CSOAA-DTPA and CSOAA-DTPA-Gd nanoprobes.
Nanoprobe Mean diameter (nm) 
CSOAA 177.03 ± 2.75 
CSOAA-DTPA 177.90 ± 18.79 
CSOAA-DTPA-Gd 146.30 ± 5.51 
alues are presented as means ± standard deviation (SD) (n = 3).
oncentration of all samples was 1 mg/ml. of CSOAA-DTPA-Gd. (B) FT-IR spectra of CSOAA-DTPA and CSOAA-DTPA-Gd.
cytotoxicity in FaDu cells in a previous report [15]; therefore, its
cytotoxicity was  not evaluated in this study. Viability (%) in both
cell types was  assessed by MTS-based assay. As shown in Fig. 3,
the cytotoxicity of CSOAA-DTPA and CSOAA-DTPA-Gd seemed to
be inconsequential in both cell lines at the probe concentrations
and incubation times (12 and 24 h) used. Although Gd has been
used as a representative T1-weighted contrast agent, the aqueous
Gd3+ ion exhibited severe cytotoxicity [7]. Therefore, organic linear
Polydispersity index Zeta potential (mV)
0.20 ± 0.02 12.50 ± 0.81
0.09 ± 0.01 9.21 ± 0.85
0.20 ± 0.05 11.19 ± 0.39
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Fig. 2. Characteristics of the CSOAA-based nanoprobe. (A) The mean diameter of the nanoprobe was  plotted according to its concentration (0.5–5 mg/ml). Data are expressed
as  means ± SD (n = 3). (B) TEM image of the nanoprobe (2.5 mg/ml). The scale bar in TEM images represents 1 m.  (C) The size distribution of the nanoprobe (2.5 mg/ml).
(D)  CAC determination of the CSOAA-based nanoprobe. The fluorescence intensity ratio (I373/I383, I1/I3) was  plotted according to nanoprobe concentration and the CAC was
estimated from the threshold concentration of the nanoprobe.
Concentration (µ g/ml) Concentration (µg/ml)
Concentration (µ g/ml) Concentration (µg/ml)










































































































Fig. 3. In vitro cytotoxicity tests of the CSOAA-based nanoprobe in (A) Hep-2 and (B) FaDu cells after 12 and 24 h of incubation. Cell viability (%) was measured by MTS-based
assay  according to nanoprobe concentration. Data are expressed as means ± SD (n = 4).








































segment is expected to facilitate loading of hydrophobic drugs.
Anti-cancer drug delivery using an unmodified CSOAA nanoparticle
and its anti-tumor efficacy in a head and neck cancer model haveig. 4. Cellular uptake studies of the nanoprobe in Hep-2 and FaDu cells. Intracel
erged images of the control (no treatment), and 0.5 h, 8 h and 12 h incubation gro
epresents 10 m.
nd macrocyclic ligands (e.g. DTPA) are required to chelate Gd3+ to
educe toxicity [7,18]. CSOAA-DTPA-Gd exhibited no severe cyto-
oxicity in head and neck cancer cells (Fig. 3), implying that this
anoprobe is safe for MR  imaging.
.4. In vitro cellular uptake
The cellular uptake efficiency of the experimental nanoprobe
as determined by CLSM. The nanoprobe was labeled with Cy5.5
nd its intracellular uptake and distribution were observed. Cy5.5
as used as a NIRF imaging dye for in vivo tumor imaging in our pre-
ious studies [4,19,20]. The Cy5.5 NHS ester was  conjugated to the
mine group of CSO by amide bond formation; the Cy5.5 content of
he Cy5.5-labeled CSOAA-based nanoprobe was 0.13% (w/w). Cel-
ular uptake and distribution patterns of Cy5.5-labeled nanoprobe
ere monitored up to 12 h in both Hep-2 and FaDu cells. The Cy5.5
uorescence intensity, indicating the amount of nanoprobe taken
p by cells, increased according to incubation time in both cell types
Fig. 4).
The physicochemical properties of nanoparticles, such as mean
iameter, surface charge, morphology and composition, can influ-
nce their cellular uptake and distribution [21]. Though smaller
anoparticles with a uniform size distribution exhibit increased
ptake, other factors can play important roles in cellular uptake
f chitosan-based nanoparticles [22–24]. The surface charge of a
anoparticle can affect its cellular uptake and subsequent cellular
istribution. Electrostatic interaction between positively charged
hitosan-based nanoparticles and the negatively charged cellular
embrane can facilitate cellular binding and uptake of nanoparti-
les. The positive charge of a chitosan-based nanoparticle promoted
ts internalization rate and level in eight cell lines [25]. In addition,
ome positively charged nanoparticles escaped the lysosome and
ocalized perinuclearly. Endocytosis of the nanoprobe is thought
o be governed by its particle size (∼150 nm) and positive zeta
otential (Table 1).
.5. Phantom study
In vitro paramagnetism of Gd-DTPA (Magnevist) and CSOAA-
TPA-Gd was evaluated by 4.7-T MRI. In Fig. 5A, T1-weighted MR
mages of both formulations according to the Gd concentration
5–100 M)  are shown. As Gd concentration increased, MR sig-
als were also enhanced, as indicated by the brightness in bothptake and distribution of the Cy5.5-labeled nanoprobe were visualized by CLSM.
e shown. Red and blue indicate Cy5.5 and DAPI, respectively. The bar in the picture
groups. The MR  signals were analyzed quantitatively and a linear
relationship between the proton longitudinal relaxation rate (1/T1)
and Gd concentration was identified. T1 relaxivity (r1) was calcu-
lated using Eq. (1). T1 relaxivity of the CSOAA-based nanoprobe was
15.28 mM−1 s−1, 2.43-fold higher than that of Gd-DTPA (Magnevist)
in this investigation (Fig. 5B). In our previous report [4], a contrast-
enhancing effect of a hyaluronic acid derivative-based nanoprobe
compared to the commercial formulation (Magnevist) was found.
CSOAA also has several hydroxyl groups in its glucose ring unit
that can attract adjacent water molecules, thereby improving the
local density of water molecules [4]. This may increase the water
exchange rate in Gd molecules and lead to enhanced T1 relaxivity
[11,26].
Although therapeutic drugs were not incorporated in this study,
the formation of an internal hydrophobic core due to the AAFig. 5. In vitro MRI  test of Magnevist (Gd-DTPA) and CSOAA-DTPA-Gd at 4.7-T. (A)
T1-weighted phantom image with 5–100 M Gd concentrations was shown. (B)
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een reported previously [15]. Therefore, although it is expected
hat the theranostic nanoparticle based on CSOAA is feasible for
ancer therapy and diagnosis, further studies of its usefulness are
equired.
. Conclusions
Self-assembled CSOAA-based nanoprobes including a T1 con-
rast agent was developed for MR  imaging. DTPA was conjugated
o CSOAA via an amide bond and Gd3+ was chelated to the DTPA
igand. This created a spherical nanoprobe of ∼150 nm mean diam-
ter with a positive zeta potential. The CSOAA-based nanoprobe
xhibited negligible cytotoxicity in head and neck cancer cell lines.
ellular uptake and distribution of the Cy5.5-labeled nanoprobe
ere also observed by CLSM and the amount of nanoprobe taken
p in head and neck cancer cells increased according to incuba-
ion time. The T1 contrast-enhancing effect of the CSOAA-based
anoprobe, compared to the commercial formulation (Magnevist),
as demonstrated in a phantom study. These results suggest that
he CSOAA-based nanoprobe is a promising MR  imaging probe for
ancer diagnosis.
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a  b  s  t  r  a  c  t
Doxorubicin  (DOX)-loaded  nanoparticles  based  on  polyethylene  glycol-conjugated  chitosan
oligosaccharide-arachidic  acid  (CSOAA-PEG)  were  explored  for potential  application  to leukemia
therapy.  PEG  was  conjugated  with  CSOAA  backbone  via  amide  bond  formation  and  the  final  product  was
verified  by 1H NMR  analysis.  Using  the  synthesized  CSOAA-PEG,  nanoparticles  having  characteristics  of
a  166-nm  mean  diameter,  positive  zeta  potential,  and  spherical  shape  were  produced  for  the  delivery  of
DOX. The  mean  diameter  of CSOAA-PEG  nanoparticles  in the serum  solution  (50%  fetal  bovine  serum)
remained  relatively  constant  over  72 h  as  compared  with  CSOAA  nanoparticles  (changes  of 20.92%
and  223.16%,  respectively).  The  sustained  release  pattern  of  DOX  from  CSOAA-PEG  nanoparticles  was
displayed  at  physiological  pH, and the  release  rate  increased  under  the  acidic  pH conditions.  The  cytotox-oxorubicin
eukemia
rolonged blood circulation
icity of the  CSOAA-PEG  conjugate  was  negligible  in  human  leukemia  cells  (K562)  at  the  concentrations
tested  (∼100  g/ml).  The  uptake  rate  of  DOX  from  the  nanoparticles  by K562  cells  was  higher  than  that
from  the  solution.  Judging  from  the  results  of  pharmacokinetic  studies  in  rats,  in  vivo  clearance  rate  of
DOX  from  the  CSOAA-PEG  nanoparticle  group was  slower  than  other  groups,  subsequently  extending  the
circulation  period.  The  PEGylated  CSOAA-based  nanoparticles  could  represent  an  effective  nano-sized
delivery  system  for  DOX  which  has  been  used  for the  treatment  of blood  malignancies.. Introduction
Nano-sized carriers have been developed for anti-cancer drug
elivery to tumor regions to overcome the intrinsic drawbacks
f using the pure drug, which include a short half-life and unde-
ired distribution to normal tissues and organs (Bae et al., 2007;
ho et al., 2011; ElBayoumi and Torchilin, 2009; Jin et al., 2012;
u et al., 2010; Xiao et al., 2012; Yang et al., 2007). Several
pproaches for modifying the surfaces of nanovehicles to mod-
late the pharmacokinetic and pharmacodynamic properties of
rugs have been investigated. Shielding groups, adsorbed or conju-
ated to the surface of nanoparticles, can disturb the electrostatic
nd hydrophobic interactions between opsonins and nanoparticles
Owens and Peppas, 2006). Among them, PEG has been grafted
r adsorbed onto the drug itself or polymers (Cho et al., 2012b;
aminskas et al., 2013; Veronese et al., 2005). It is known that an
∗ Corresponding author. Tel.: +82 33 250 6916; fax: +82 33 259 5631.
∗∗ Corresponding author. Tel.: +82 2 880 7870; fax: +82 2 873 9177.
E-mail addresses: hjcho@kangwon.ac.kr (H.-J. Cho), ddkim@snu.ac.kr
D.-D. Kim).
378-5173/$ – see front matter © 2014 Elsevier B.V. All rights reserved.
ttp://dx.doi.org/10.1016/j.ijpharm.2014.01.015© 2014  Elsevier  B.V.  All  rights  reserved.
outer PEG shell can prevent the opsonization of nanoparticles in
the blood and maintain their camouflage for phagocytosis (Owens
and Peppas, 2006). Thus, this “stealth effect” can enhance systemic
drug exposure and prolong circulation of nanocarriers in the blood
stream. It has also been reported that the density of the PEG chain on
the surface of nanoparticles may  affect their interaction with blood
components and macrophages (Owens and Peppas, 2006). Studies
of the influence of PEG conjugation to various polymeric nanopar-
ticles, for anti-cancer drug delivery, on the blood circulation time
and anti-tumor efficacy have been reported (Cho et al., 2012b; Lv
et al., 2012; Qu et al., 2009; Yadav et al., 2011). Moreover, a PEG
shell on nanoparticles containing anti-cancer agents reduced their
hematological toxicity after intravenous administration (Jain et al.,
2012); thus, it can be used to mask the toxicity of polymeric matrix
in the blood stream.
Natural polymers and their derivatives have been widely used
for the development of self-assembled nanoparticles for cancer
therapy and diagnosis (Cho et al., 2012a; Chung et al., 2013;
Lee et al., 2011; Nogueira et al., 2013). In our previous reports
(Termsarasab et al., 2013a,b), chitosan oligosaccharide-arachidic
acid (CSOAA), as an amphiphilic chitosan oligosaccharide deriva-



























































placed in 15 ml  of phosphate-buffered saline (PBS: pH 5.5, 6.8,
and 7.4, adjusted with phosphoric acid). The drug release test was
conducted in a shaking bath at 37 ◦C and 50 rpm rotation speed.28 U. Termsarasab et al. / International Jo
SOAA were prepared. CSOAA-based nanoparticles were developed
or delivery of anti-cancer drugs to the tumor region and cancer
iagnosis. Although anti-tumor efficacy after intravenous injection
ased on passive targeting strategy, mainly due to the enhanced
ermeability and retention (EPR) effect, has been achieved in a
ead and neck cancer xenograft mouse model, the nanoparticles
eveloped may  exhibit greater in vivo anti-tumor efficacy as a
esult of the surface modification. Here, PEGylated CSOAA-based
anoparticles were prepared in an effort to prolong their circulation
n the blood stream after intravenous administration. CSOAA-PEG
onjugate was synthesized, and the physicochemical properties
f CSOAA-PEG nanoparticles were investigated. Their application
or leukemia therapy was tried and the alterations in the phar-
acokinetic properties of the drug were assessed in an animal
odel.
. Materials and methods
.1. Materials
Chitosan oligosaccharide (CSO; average molecular
eight = 5 kDa, deacetylation degree > 90%) was obtained from
itto Life Co., Ltd. (Seoul, Korea). Arachidic acid (AA), 1-ethyl-3-
3-dimethylaminopropyl) carbodiimide (EDC), N-hydro-
ysuccinimide (NHS), deuterochloroform (CDCl3) and deuterium
xide (D2O) were purchased from Sigma–Aldrich Co. (St. Louis,
O,  USA). Methoxypolyethylene glycol succinimidyl succinate
mPEG-SS; molecular weight = 2 kDa) was provided by Sunbio Co.
Anyang, Korea). Doxorubicin hydrochloride (DOX HCl) was  pur-
hased from Boryung Pharmaceutical Co., Ltd. (Seoul, Korea). RPMI
640 medium, penicillin, streptomycin, and heat-inactivated fetal
ovine serum (FBS) were purchased from Gibco Life Technologies
nc. (Grand Island, NY, USA). All other reagents were of analytical
rade and were obtained from commercial sources.
.2. Synthesis and characterization of CSOAA-PEG
CSOAA was synthesized as described in our previous report,
ith slight modifications (Termsarasab et al., 2013a). Briefly, CSO
0.2 mmol) and AA (1 mmol) were solubilized in 25 ml  dimethyl
ulfoxide (DMSO) separately at 50 ◦C for 15 min  and cooled to
oom temperature. EDC (1.5 mmol) and NHS (1.5 mmol) were
dded to the AA solution and stirred for 30 min. Then, the AA
olution was added to the CSO solution; the reaction was  con-
ucted for 12 h with stirring. That solution was then adjusted to
H 3.5 with 1 N HCl, prior to precipitating with 450 ml  acetone
hree times to remove unreacted AA. The precipitate was  collected
y centrifugation (8608 × g, 30 min), and resuspended in 50-ml
ouble-distilled water (DDW). This solution was dialyzed (dialysis
embrane molecular weight cut-off = 1 kDa; Spectrum Laborato-
ies, Laguna Hills, CA, USA) against DDW for 2 days. CSOAA was
btained after freeze-drying.
To synthesize CSOAA-PEG, CSOAA (0.125 mmol) was  solubilized
n 30-ml DMSO, followed by addition of mPEG-SS (0.25 mmol).
fter stirring for 12 h, the solution was dialyzed (dialysis mem-
rane molecular weight cut-off = 3.5 kDa) against DDW for 1 day
nd then freeze-dried. The freeze-dried product was precipitated
y adding excess acetone to remove unreacted mPEG-SS. The
recipitate was collected by filtering and dried at 60 ◦C. The con-
ugations of CSOAA and CSOAA-PEG were confirmed by 1H NMR
nalysis (Varian FT 500-MHz, Varian Inc., Palo Alto, CA, USA). To
repare the 1H NMR  samples (15 mg/ml  concentration), CSOAA and
SOAA-PEG were dissolved in D2O and mPEG-SS was  solubilized
n CDCl3, respectively. Standard samples were prepared by mixing
PEG-SS and CSOAA at various molar ratios (0.5:1, 1:1, 1:2, 1:3,of Pharmaceutics 464 (2014) 127–134
and 1:4) and freeze-drying for the determination of molar substi-
tution (MS) of CSOAA-PEG. The MS  of CSOAA-PEG was  calculated
based on the ratio of the integration values of the CSOAA and
mPEG-SS 1H NMR  spectra. Those substances were dissolved in
DMSO-d6.
2.3. Preparation and characterization of DOX-loaded
nanoparticles
DOX-loaded CSOAA and CSOAA-PEG nanoparticles were pre-
pared by a solvent evaporation method as reported previously
(Termsarasab et al., 2013a). DOX base was  prepared by the reac-
tion between DOX HCl and triethylamine in DMSO for 12 h and
lyophilization. CSOAA or CSOAA-PEG and DOX base (7.5:1.5, w/w)
were dissolved in DMSO and DDW mixture (1:1, v/v). The solvent
was removed under a nitrogen gas stream at 70 ◦C for 4 h. The drug
and polymer film coated-tube was hydrated with DDW, followed
by sonication using a probe sonicator (Vibra-Cell, Sonics & Materi-
als Inc., CT, USA) for 5 min. The nanoparticle suspension was then
filtered through a syringe filter with 0.45-m pore size (Minisart RC
15; Satorius Stedim Biotech GmbH, Gottingen, Germany) to remove
unloaded DOX.
The average mean diameter, polydispersity index, and zeta
potential values of DOX-loaded CSOAA and CSOAA-PEG nanopar-
ticles in DDW were measured using a dynamic light scattering
(DLS) spectrophotometer (ELS-Z; Otsuka Electronics Co. Ltd., Osaka,
Japan). Change of particle size (nm) in DDW and 50% (v/v) FBS
was also measured according to the incubation time (0.5, 1, 1.5,
2, 4, 6, 24, 48, and 72 h). The morphology of nanoparticles was
observed by transmission electron microscopy (TEM; LIBRA 120;
Carl Zeiss, Oberkochen, Germany). Samples were stained with
2% (w/v) phosphotungstic acid, loaded on a copper grid coated
with carbon film, and dried at 20 ◦C. To determine the encap-
sulation efficiency (EE) of the drug, aliquots of samples (0.1 ml
of each nanoparticle suspension) were diluted with a 100× vol-
ume  of DMSO to disrupt the nanoparticles. DOX content was
analyzed by a high-performance liquid chromatography (HPLC)
method using a Waters HPLC system (Waters Co., Milford, MA,
USA) equipped with a reversed-phase (RP) C-18 column (Xbridge,
RP-18, 250 mm × 4.6 mm,  5 m;  Waters Co.), a separation mod-
ule (Waters e2695), and a fluorescence detector (Waters 2475).
The mobile phase consisted of 10 mM K2HPO4 (pH 2.5) and 0.01%
(v/v) triethylamine in acetonitrile (71:29, v/v) with a flow rate of
1 ml/min. The excitation and emission wavelengths were 470 and
565 nm,  respectively. The injection volume was 20 l. The inter-
day and intra-day variances were within the acceptable range. The
EE value of DOX in nanoparticles was  determined by the following
equation:
EE (%) = actual amount of drug in nanoparticles
theoretical amount of drug in nanoparticles
×  100 (1)
2.4. In vitro DOX release test
DOX-loaded CSOAA or CSOAA-PEG nanoparticles (150 l) were
loaded in a mini GeBA-flex tube (molecular weight cut-off:
12–14 kDa, Gene Bio-Application Ltd., Kfar Hanagide, Israel) andAliquots of release medium (200 l) were collected at set times (1,
2, 3, 4, 6, 9, 12, 24, 48, 72, 96, and 120 h), and an equivalent volume
of fresh medium was replaced. The amount (%) of DOX released was
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.5. In vitro cytotoxicity of CSOAA and CSOAA-PEG
Human leukemia K562 cells were purchased from the
orean Cell Line Bank (Seoul, Korea). The cells were cul-
ured in RPMI 1640 medium containing 10% FBS, 100 U/ml
enicillin, and 100 g/ml streptomycin at 37 ◦C in a 5% CO2
tmosphere and 95% relative humidity. The cytotoxicities of
SOAA and CSOAA-PEG to K562 cells were determined using
 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-
ulfophenyl)-2H-tetrazolium (MTS)-based assay. Various concen-
rations (∼100 g/ml) of CSOAA and CSOAA-PEG were added to
 × 104 cells suspended in 100-l culture media and incubated for
4, 48, and 72 h. Then, the cells were treated with the MTS-based
ellTiter 96 AQueous One Solution Cell Proliferation Assay Reagent
Promega Corp., Madison, WI,  USA) at 37 ◦C for 4 h, according to the
anufacturer’s protocol. The absorbance at 490 nm was  measured
sing a microplate reader (EMax, Molecular Devices, Sunnyvale,
A).
.6. In vitro cellular uptake study
K562 cells at a density of 6 × 105 per well were treated with free
OX, DOX-loaded CSOAA nanoparticles, or CSOAA-PEG nanoparti-
les at an equivalent DOX concentration (15 g/ml). After the cells
ere incubated for 1 h, they were washed with PBS (pH 7.4) and
esuspended in medium with 2% (v/v) FBS. DOX uptake efficiency
as evaluated by flow cytometry using a FACSCalibur equipped
ith the CELLQuest software (Becton Dickinson Biosciences, San
ose, CA, USA).
.7. In vivo pharmacokinetics in rats
Animal study protocol was approved by the Institutional Ani-
al  Care and Use Committee of Seoul National University (Seoul,
orea). Male Sprague-Dawley (SD) rats, weighing 250–300 g (Ori-
nt Bio, Inc., Seongnam, Korea), were used. The rats were housed
nder standard room (Animal Center for Pharmaceutical Research,
ollege of Pharmacy, Seoul National University) at a temperature
f 20–23 ◦C and a relative humidity of 50 ± 5%. A polyethylene tube
PE-50; Clay Adams, Parsippany, NJ, USA) was cannulated into
he femoral veins and arteries of rats under ketamine anesthesia
50 mg/kg, intramuscular injection). Each group was administered
t a single dose of 4 mg/kg DOX intravenously via the femoral
ein. Blood samples (300 l) were then collected via the femoral
rtery at 0, 2, 5, 15, 30, 60, 90, 120, 180, 240, 360, and 480 min and
entrifuged (16,000 × g, 5 min). Aliquots (150 l) of plasma were
tored at −20 ◦C until the quantitative analysis of DOX. The DOX
oncentration in plasma was analyzed by a reported HPLC method
Cho et al., 2012b) with slight modifications. An aliquot of plasma
ample (150 l) with propranolol solution (internal standard,
0 l, 1 g/ml) was mixed with acetonitrile (400 l). After vortex-
ng and centrifuging (16,000 × g, 10 min), supernatant (300 l) was
ransferred to a clean tube and evaporated under a gentle stream
f nitrogen at 40 ◦C. The residue was reconstituted with 60-l
obile phase (a mixture of 10 mM K2HPO4 (pH 2.5) and 0.01%
v/v) triethylamine in acetonitrile, 73:27, v/v). After vortexing and
entrifuging, a 10-l aliquot was subjected to HPLC analysis. The
amples were injected into the RP-HPLC column as described above.
he fluorescence intensity was monitored at excitation/emission
avelengths of 470/565 nm for DOX, and 230/540 nm for propra-
olol. The lower limit of quantification (LLOQ) value of DOX in rat
lasma was 0.01 g/ml. The intra-day and inter-day coefficients of
ariation were within the acceptable range. The total area under
he plasma concentration–time curve from time zero to infinity
AUC), terminal half-life (t1/2), time-averaged total body clearance
CL), apparent volume of distribution at steady state (Vss), andf Pharmaceutics 464 (2014) 127–134 129
mean residence time (MRT) were calculated using the WinNonlin
software (Pharsight, Mountain View, CA, USA).
2.8. Statistical analysis
Statistical analysis was conducted using t-test and analysis of
variance (ANOVA). All experiments were performed at least three
times. The data are shown as means ± standard deviation (SD).
3. Results and discussion
3.1. Synthesis of CSOAA-PEG
PEGylated CSOAA was synthesized to develop nanoparticles for
DOX delivery. The synthetic method for CSOAA was reported in
our previous study (Termsarasab et al., 2013a). Briefly, CSOAA was
synthesized by a coupling reaction between the amine groups of
CSO and carboxyl groups of AA using EDC and NHS as coupling
reagents. EDC was introduced into the carboxyl groups of AA, and
an AA-NHS intermediate was formed by adding NHS to EDC active
ester. This intermediate was reacted with the amine group of CSO to
generate CSOAA. Then, mPEG-SS was introduced to the remaining
amine groups of CSOAA. To characterize the structure of CSOAA
and CSOAA-PEG, 1H NMR  analyses of mPEG-SS, CSOAA, and CSOAA-
PEG were performed; their spectra are shown in Fig. 1. The proton
peaks of the alkyl chain and methyl group of AA appeared at 1.2 and
0.8 ppm, respectively. The specific proton peaks for the oxyethy-
lene group ( CH2CH2O ) and methoxy group (CH3O ) of mPEG
appeared at 3.5–3.7 ppm and 3.3 ppm, respectively. The proton
peaks between 2.5 and 3.0 ppm were corresponded to the succin-
imidyl succinate group of mPEG-SS. Compared with CSOAA and
mPEG-SS, the 1H NMR  spectrum of CSOAA-PEG exhibited the spe-
cific proton peaks of CSOAA and mPEG, while the proton peak of
the succinimidyl succinate group shifted to 2.2 ppm. These results
confirmed PEG conjugation to CSOAA. A homogeneous physical
mixture of CSOAA and PEG was  prepared and each component was
analyzed by 1H NMR  to calculate the molar substitution (MS) of
PEG to CSOAA, according to a modified method reported previ-
ously (Termsarasab et al., 2013a). The molar substitution of PEG
to CSOAA was  calculated using the linear regression line, which
was plotted between the integration ratio of the methoxy group of
PEG (ı = 3.3; CH3O ) to the N-acetyl proton group of CSO (ı = 1.8;
CH3CONH ), and the molar ratio of mPEG-SS to CSOAA prepared
from standard samples (data not shown). The molar substitution
(mole of mPEG-SS/mole of CSOAA) of PEG to CSOAA was 1.8 in this
investigation.
3.2. Preparation and characterization of DOX-loaded
nanoparticles
Based on the CSOAA-PEG synthesized, nanoparticles loaded
with DOX were prepared using a solvent evaporation method
(Termsarasab et al., 2013a). In this study, CSOAA/DOX and CSOAA-
PEG/DOX, at a weight ratio of 7.5–1.5 (polymer to drug), nanopar-
ticles were prepared. The mean diameters of the CSOAA/DOX
and CSOAA-PEG/DOX nanoparticles were 124.17 ± 2.58 and
165.75 ± 6.75 nm,  respectively (Table 1). As shown in Fig. 2, TEM
image of the CSOAA-PEG/DOX nanoparticles showed a spheri-
cal shape and similar particle size to that measured by ELS. The
hydrophilic PEG, conjugated to CSOAA, constituted the outer shell
of the nanoparticles (Fig. 2). Because of this PEG shell, the mean
diameter of drug-loaded CSOAA/PEG nanoparticles was increased
versus drug-loaded CSOAA nanoparticles. This phenomenon was
also reported by us previously (Cho et al., 2012b) for amphiphilic
hyaluronic acid oligomer-based nanoparticles. Despite the outer
hydrophilic PEG shell on the CSOAA-based nanoparticles, the mean
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Fig. 1. 1H NMR  spectra of CSOAA, mPEG-SS, and CSOAA-PEG. CSOAA and CSOAA-PEG were solubilized in D2O, and mPEG-SS was dissolved in CDCl3.
Table 1
Characteristics of DOX-loaded CSOAA and CSOAA-PEG nanoparticles (n ≥ 3).
Formulations (w/w) Mean diameter (nm) Polydispersity index Zeta potential (mV) Encapsulation efficiency (%)
CSOAA/DOX (7.5/1.5) 124.17 ± 2.58 0.20 ± 0.04 27.28 ± 1.50 60.03 ± 2.14
CSOAA-PEG/DOX (7.5/1.5) 165.75 ± 6.75 0.19 ± 0.03 21.47 ± 2.05 63.80 ± 3.19
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ig. 2. Characterization and illustration of CSOAA-PEG/DOX nanoparticles. (a) Size
re  shown. Differential intensity (%) of the diameter of CSOAA-PEG/DOX nanopartic
f  DOX-loaded CSOAA-PEG nanoparticles is shown.
iameter was less than 200 nm,  indicating a low probability of
eticuloendothelial system (RES) clearance (Gaucher et al., 2005).
he polydispersity index of PEGylated CSOAA-based nanoparticles
ontaining DOX was 0.19 ± 0.03, indicating a narrow size distri-
ution (Fig. 2). The zeta potential value of the CSOAA-PEG/DOX
anoparticles was lower than that of the CSOAA/DOX nanopar-
icles (p < 0.05), possibly due to the presence of the outer PEG
hell.
The mean diameters of drug-loaded CSOAA and CSOAA-PEG
anoparticles were measured in DDW and those values of both
anoparticle groups were constantly maintained for 72 h (Fig. 3a).
owever, they are not enough to reflect the actual particle size in
he blood stream. Additionally, in vivo pharmacokinetic and phar-
acodynamic performances cannot be predicted precisely from
article size measurements in DDW. Nanoparticles administered
y the intravenous route can interact with blood components
nd form large aggregates or complexes (Liu et al., 2012; Rausch
t al., 2010). These unwanted aggregates can inhibit normal blood
irculation and are readily eliminated by RES organs (liver and
pleen). Thus, changes in particle size in the presence of serum (50%,
/v) were monitored according to the incubation time. As shown
n Fig. 3b, the mean diameter of CSOAA-PEG/DOX nanoparticles
ncreased by 20.92% over 72 h, while CSOAA/DOX nanoparticles
howed a 223.16% increase in mean diameter during the same
eriod. The hydrophilic PEG shell of CSOAA-PEG/DOX nanopar-
icles hampered the interaction between blood constituents and
he chitosan-based surface, and thus reduced the aggregation of
anoparticles in the presence of serum. Maintaining the initial
ean diameter of PEGylated nanoparticles under serum conditions
an lead to the improved stability by “stealth effect” (Qu et al.,bution (left panel) and TEM image (right panel) of CSOAA-PEG/DOX nanoparticles
presented. The bar in the TEM image represents 100 nm.  (b) Schematic illustration
2009; Zhang et al., 2013), and thereby prolonging circulation of
the nanoparticles in the blood stream.
3.3. In vitro drug release
DOX release in vitro from the nanoparticle formulations was
monitored at pH 5.5, 6.8, and 7.4 (Fig. 4). DOX release profiles
from CSOAA-based nanoparticles under several pH conditions have
been reported previously (Termsarasab et al., 2013a). Despite dif-
ferent weight ratios between CSOAA and DOX compared with the
current study, DOX release was  improved in acidic pH condition.
In this investigation, the proportions (%) of DOX released from
CSOAA and CSOAA-PEG nanoparticles after 24 h were 56.69 ± 4.04%
and 31.19 ± 0.95%, respectively. After a steady increase in DOX
release from the CSOAA-PEG nanoparticles, the two values reached
56.02 ± 2.07% and 50.77 ± 5.88%, respectively, at day 5. Although
the proportions of DOX released from both nanoparticle formu-
lations were similar at steady state (around day 5), a sustained
pattern of DOX release from the CSOAA-PEG nanoparticles was
observed. Thus the PEG shell may  delay drug diffusion and disso-
lution from the reservoir. Sustained drug release from PEGylated
nanoparticle formulations has been reported previously (Cho et al.,
2012b; Jain et al., 2012). Additionally, pH-dependent DOX release
from CSOAA-PEG nanoparticles was  observed. The proportions of
DOX released from CSOAA-PEG nanoparticles at pH 7.4 and 5.5
on day 5 were 50.77 ± 5.88% and 83.57 ± 0.24%, respectively. This
can be explained by the higher solubility of DOX  under acidic pH
conditions and changes in the binding strength between the drug
and nanoparticle structure (Jin et al., 2012; Nukolova et al., 2011;
Termsarasab et al., 2013a). Enhanced DOX release at pH 5.5 and 6.8,
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hich reflects the conditions in endocytic compartments (endo-
omes and lysosomes, pH 5.5) and the tumor microenvironment
pH 6.8), may  facilitate DOX uptake into cancer cells and so enhance
ts anti-tumor effect.
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ig. 4. In vitro DOX release profiles of CSOAA and CSOAA-PEG-based nanoparticles.
rug release profiles of DOX-loaded CSOAA nanoparticles (pH 7.4) and CSOAA-PEG
anoparticles at pH 5.5, 6.8, and 7.4 are shown. Each point represents the mean ± SD
n  = 3).Fig. 5. In vitro cytotoxicity test of CSOAA (a) and CSOAA-PEG (b) in K562 cells.
Each conjugate at various concentrations was  incubated for 24, 48, and 72 h in the
presence of K562 cells. Each point represents the mean ± SD (n = 4).
3.4. In vitro cytotoxicity
The cytotoxicity of CSOAA and CSOAA-PEG was  assessed against
K562 cells, human erythromyeloblastoid leukemia cells (Laroche-
Clary et al., 2000), using an MTS-based assay. Cell viability (%) is
presented after 24, 48, and 72 h of incubation with various con-
centrations of both conjugates (Fig. 5). One of the indications for
DOX is leukemia; thus, K562 cells were used for determination
of the cytotoxicity of the conjugates synthesized. Neither CSOAA
nor CSOAA-PEG induced serious toxic effects in K562 cells at the
concentrations tested after incubation for 24–72 h. In our previous
study (Termsarasab et al., 2013a), CSOAA also showed no significant
cytotoxicity in head and neck cancer cell line (FaDu cell). Our results
here suggest that CSOAA-PEG can be used safely for the preparation
of drug delivery vehicle.
3.5. In vitro cellular uptake
The cellular uptake efficiency of DOX from the nanoparticles
developed was  assessed using flow cytometry. In this investigation,
the K562 cell was selected as a model cell line of human leukemia.
DOX has been used in leukemia therapy in the clinic; thus, its
uptake into K562 cells could be related to its anti-tumor efficacy. As
shown in Fig. 6, DOX uptake was higher in the nanoparticle-treated
groups than the DOX solution-treated group. This might be due
to the electrostatic interaction between the positive charge of the
U. Termsarasab et al. / International Journal of Pharmaceutics 464 (2014) 127–134 133
F X-loaded CSOAA nanoparticles (blue), and DOX-loaded CSOAA-PEG nanoparticles (green)





























































ig. 6. Flow cytometry analysis of DOX uptake by K562 cells. DOX solution (red), DO
ere  incubated for 1 h. (For interpretation of the references to color in this figure le
hitosan molecules and the negative charge of the cell membrane
Chavanpatil et al., 2006; Termsarasab et al., 2013a; Zauner et al.,
998). As reported in other cell line (Termsarasab et al., 2013a),
OX uptake from CSOAA-based nanoparticle was  enhanced com-
ared with DOX solution in K562 cells. However, the cellular uptake
f DOX from the PEGylated CSOAA-based nanoparticles was  lower
han from CSOAA-based nanoparticles. This may  be explained by
he outer PEG shell reducing the electrostatic force between chi-
osan and the cell membrane, blocking interactions between the
atty acids in the minor hydrophobic core of the nanoparticles and
he cell membrane, thus delaying drug release. Notwithstanding
he lower cellular uptake efficiency of PEGylated CSOAA nanoparti-
les, they may  exert a stealth effect, due to the prolonged circulation
ime in the blood stream after intravenous injection.
.6. In vivo pharmacokinetics in rats
DOX-loaded nanoparticles were administered intravenously at
 dose of 4 mg/kg to rats to investigate their effects on the phar-
acokinetic properties of DOX. The DOX concentration in plasma
ccording to time is shown in Fig. 7, and the pharmacokinetic
arameters are listed in Table 2. The pharmacokinetic parameters
f a DOX solution (4 mg/kg dose)-treated group reported in our
revious study (Cho et al., 2012b) were used as the control. CL val-
es of CSOAA and CSOAA-PEG nanoparticle groups were decreased,
o 11.17% and 2.09% of the value of DOX solution. AUC values of
SOAA and CSOAA-PEG nanoparticle groups exhibited 8.64- and
8.00-fold increases compared with that of the DOX solution group,
espectively. Half-life (t1/2) values in both groups were increased to
73.50% and 899.82%, respectively, compared with that of the DOX
olution group. Additionally, MRT  values showed 10.52- and 47.58-
old increases compared to the DOX solution group. These data
able 2
harmacokinetic parameters of DOX in rats after intravenous administration at a dose of 
Parameter DOX solutiona
AUC (g ·min/ml) 65.18 ± 16.47#
Terminal t1/2 (min) 76.37 ± 8.83#
CL (ml/min/kg) 63.76 ± 14.18#
Vss (ml/kg) 1189.49 ± 204.99 
MRT  (min) 18.82 ± 1.14#
ata present as mean ± SD (n ≥ 3).
a Data were cited from our previous report (Cho et al., 2012b).
# p < 0.05, significantly different from the other groups.tered intravenously at a dose of 4 mg/kg (DOX). Each point represents the mean ± SD
(n  ≥ 3).
indicated that the nanoparticles developed here exhibited lower
in vivo clearance of DOX and prolonged circulation of nanoparti-
cles in the blood stream. The PEGylated nanoparticles also showed
decreased in vivo clearance, and increased AUC, half-life, and MRT
values, compared with CSOAA-based nanoparticles (p < 0.05). It
has been reported that nanoparticles modified with PEG exhibited
enhanced systemic exposure of the drug after intravenous injec-
tion (Qu et al., 2009; Zhang et al., 2013). The decreased in vivo
clearance of DOX in the PEGylated CSOAA nanoparticles seems
to be based on their greater stability in the presence of serum
4 mg/kg.
CSOAA/DOX CSOAA-PEG/DOX
563.24 ± 33.34# 3128.65 ± 621.52#
132.50 ± 32.80# 687.19 ± 221.97#
7.12 ± 0.41# 1.33 ± 0.31#
1195.81 ± 192.67 1117.43 ± 207.24


































Zauner, W.,  Ogris, M.,  Wagner, E., 1998. Polylysine-based transfection systems uti-34 U. Termsarasab et al. / International Jo
Fig. 3) and sustained drug release (Fig. 4). The stealth effect of
he PEG shell likely contributes to the longer dosing interval and
mproved anti-tumor efficacy. In particular, prolonged circulation
f the CSOAA-PEG nanoparticles developed may  be appropriate for
he therapy of hematological malignancies, such as leukemia and
ymphoma.
. Conclusions
PEGylated CSOAA-based nanoparticles containing DOX were
eveloped to achieve a prolonged circulation time of the drug in
he blood stream. Synthesis of the CSOAA-PEG conjugate was con-
rmed by 1H NMR  analysis. DOX-loaded CSOAA-PEG nanoparticles
ith a ∼166-nm mean diameter and positive zeta potential were
repared and a sustained pattern of drug release from the CSOAA-
EG nanoparticles was observed. The cytotoxicity of CSOAA-PEG
n K562 cells seemed negligible in the concentration range tested,
nd the cellular uptake efficiency of the drug from nanoparticles
as improved compared with DOX in solution. Decreased in vivo
learance and a longer DOX half-life in the blood stream in the
SOAA-PEG nanoparticles group was demonstrated in a pharma-
okinetic study. The CSOAA-PEG nanoparticle developed may  be a
seful candidate of anti-cancer drug delivery system, especially for
he treatment of blood cancers.
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